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Abstract
Radiofibrosis of the breast makes satisfactory breast tissue reconstruction challenging and is
associated with complications. Autologous fat grafting can improve surgical outcomes but fat
retention is variable. We developed RHAMM mimetic peptides (NPI-110) that decrease tissue
fibrosis and increase mammary fat pad adipogenesis by promoting the differentiation of
mesenchymal progenitor cells into adipocytes. We tested the efficacy of NPI-110 in a rat model of
radiation-induced mammary fat pad fibrosis. Effects of radiation and NPI-110 were quantified by
visible skin changes, fat pad volume estimates using high frequency ultrasound, mRNA expression
of genes involved in fibrosis (Collagen-1:Collagen-1, TGFß1) and adipogenesis (PPARγ,
adiponectin and perilipin) using qPCR, and collagen fibril deposition using picrosirius red staining.
NPI-110 significantly reduced skin inflammation and radiofibrosis, the latter assessed by collagen
fibril deposition, and increased mRNA expression of adipogenic markers. Results from this study
will aid in creating a micro-environment that optimizes fat transplantation success.
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Introduction

1 in 9 Canadian women will be diagnosed with breast cancer in her lifetime, and 1 in 30 will die
from it1. Approximately 45 to 50% breast cancer patients undergo curative radiotherapy2–4. Recent
data have shown that post-mastectomy radiation therapy reduced the rate of loco-regional
recurrence in node-positive patients from 9 to 27%5.
Although there are newer radiotherapy techniques that reduce skin and overall toxicity, acute skin
toxicity, chronic inflammation, and tissue fibrosis still occur6,7. The underlying mechanisms
driving radiation-induced chronic inflammation and fibrosis are not well understood, and so there
are no effective interventions to prevent or modify the course and severity of this damage3,7–9.
In the context of plastic surgery, breast reconstruction in the irradiated breast is a challenge. Fat
grafting has emerged as a technique that improves contour abnormalities, reduces tissue fibrosis,
scar formation, and post-mastectomy pain10. There is also early evidence that fat grafting improves
scar formation following radiation and enhances quality of soft tissue envelope. However, fat take
is variable, with the prevailing theory that successful grafting results from the survival and
differentiation of pre-adipocyte and other adipose derived multi-potent stem cells (ASCs) in the
graft11.

1.1 Radiation Damage
The use of ionizing radiation is predicated on attempting to achieve lethal effects on tumour cells
while sparing normal tissue12. The majority of breast cancer patients, however, still develop
radiation-induced skin toxicity and underlying tissue fibrosis2.
Radiation injury may be categorized as acute or chronic (late), with acute injury occurring within
hours to weeks after radiation exposure, and chronic injury presenting months to years after
radiation exposure7–9. Acute injury primarily involves skin cell death through cellular alterations
and inflammation in the epidermis, starting with erythema, edema, pigment changes, and deepilation8. Severe acute injury involves complete loss of epidermis, persistent edema, fibrinous
1

exudates and disturbance in skin barrier function8,13. The severity of skin reactions thus range from
mild erythema and dry desquamation, to moist desquamation and ulceration3,14. Later, chronic
effects include chronic inflammation, delayed ulcers, telangiectasias, atrophy, poikilodermatous
changes, necrosis, fibrosis and osteoradionecrosis, and are from other as yet poorly defined
mechanisms2,8. Factors that affect the severity of reaction include dose fraction, total dose
delivered, use of bolus or other beam-modifying devices, site, size of treatment field,
chemotherapy and individual factors15.
Newer technologies such as conformal radiation techniques and intensity-modulated radiation
therapy (IMRT) have considerably reduced the area of skin toxicity7. However, radiation
dermatitis cannot be avoided in certain areas where the skin or superficial tissues are the target,
such as breast cancer3. As a result, approximately 74-100% of breast cancer patients experience
radiation dermatitis7,16,17. While the majority of these changes resolve, there is also a trend towards
combining chemotherapy with larger fractions of radiation. Chemotherapeutic drugs can induce
radiosensitivity, which is more effective in killing tumour cells but a side effect is often severe
xerosis, inflammation, skin thinning, and skin necrosis. This condition develops into a dynamically
progressing fibrosis with reversible and irreversible components in approximately 35% of patients,
and results in a greater proportion of patients developing a persistent chronic inflammation and
localized fat pad fibrosis4,10,18,19. Radiation boosts to the tumour bed using electrons, external-beam
megavoltage photons, or interstitial brachytherapy after external whole-breast irradiation (WBI)
has been shown to reduce the risk of local recurrence following breast-conserving surgery.
However, these and more novel boost methods such as intraoperative radiation therapy (IORT)
have also been associated with an increased rate of severe subcutaneous fibrosis, as a higher total
radiation dose is delivered17. Although not life threatening, fibrotic breast tissue is challenging to
reconstruct and contribute to variability of autologous fat grafting success in these patients.
The underlying mechanisms driving the development of these radiation-associated changes are not
well understood, due in part to a lack of suitable pre-clinical models8. As a result of this knowledge
deficit, there is currently no effective intervention, by topical or systemic means, to prevent or
favorably modify the course and severity of dermatitis3,7–9. Studies and reviews have observed
interventions such as “washing with mild soap”, topical corticosteroids, non-steroidal creams,
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hyaluronic acid, ascorbic acid, silver leaf dressing, amifostine and oral enzymes for radiationinduced skin reactions3,8,9. Long treatments of Pentoxifylline and tocopherol have reduced
radiation-induced fibrosis, but are associated with undesired outcomes (e.g., their cessation results
in a “rebound effect”) 7,20.
Overall, very few studies have demonstrated statistically significant results of the aforementioned
interventions3,16. The development of effective radiation mitigators and protectors, and the
elucidation of mechanisms responsible for radiation-associated changes in skin and other normal
tissues in comparison to tumours necessary for such a task are thus of interest21. A possible genetic
basis for risk has been suggested in a study that had observed clinical heterogeneity in the
manifestation of fibrosis-related to radiation-induced dermatitis22. As such, target gene therapy and
stem cell therapy combined with surgical excision are new techniques and emerging areas of
interest8.

1.1.1 Pathophysiology
There are two discreet types of radiation: ionizing, which has enough energy to change the
chemical composition of matter and is what radiotherapy is comprised of; and nonionizing, which
has less energy, but can still excite molecules and atoms23.
Radiotherapy interferes with normal processes of epidermal and hair matrix cells, as well as
fibroblasts and cutaneous vasculature. Ionizing radiation causes various types of initial tissue
injury through two major pathways. First, an oxidative stress and radiolytic hydrolysis process
occurs that leads to the production of free radicals resulting in DNA damage and alterations of
proteins, lipids, and carbohydrates24–26. Inhibition of normal granulation tissue, angiogenesis, and
fibrogenesis occur as a result of this process24,26. Second, there is stimulation of the innate immune
system leading to tissue inflammation processes; transcriptionally activated pro-inflammatory
cytokines and growth factors result in alteration of cellular proliferation24. For example, Interleukin
1a (IL-1a) is a cytokine that initiates the interaction between epithelial and mesenchymal cells,
and modulates the synthesis of other pro-inflammatory mediators and proteases in surrounding
fibroblasts27.
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Ionizing radiation resulting in free radicals immediately produces damage to the epidermal basal
keratinocytes, hair follicle stem cells, endothelial cells, Langerhans cells, and vascular bed through
DNA damage24,25,28. These free radicals, primarily reactive oxygen species, also cause
fragmentation of extracellular matrix (ECM) proteins such as collagen, laminin, and
polysaccharides 29. The signals generated from the fragmented HA components then trigger an
influx of pro-inflammatory innate immune cells, and together result in aberrant stem cell function
and predisposes tissues to a hyper-activation of fibrotic pathways as a compensatory
mechanism8,30. These effects may persist and progress, particularly if DNA damage is incompletely
repaired. These events altogether contribute to barrier function impairment, bacterial colonization,
and superinfection24.
On a cellular level, perivascular inflammatory infiltrate around dilated blood vessels, swelling,
growth arrest, and sloughing of epithelial cells is seen in acutely irradiated skin24. Effects depend
on the radiation dose, and range from clumping of nuclear chromatin, nuclear swelling, nuclear
disfiguration, mitochondrial distortion, to cellular necrosis24,31,32. The physiology behind
telangiectasia is unknown, but is thought to be due to microvasculature damage due to
inflammation during acute injury, and the excessive production of cytokines and growth factors
such as TGFβ1, platelet-derived growth factor (PDGF) and fibroblast growth factor by
macrophages or damaged endothelial cells24,26.

1.1.2 TGFβ1
TGFβ1 is a peptide and cytokine that has many functions, of which include promoting the
development of chronic inflammation, radiation dermatitis, and fibrosis33. TGFβ1 activates
fibroblasts to secrete extracellular matrix protein including collagen24,34–36. Up-regulation of
TGFβ1 is common in the fibrotic tissues of irradiated patients and induction of its expression is a
major cellular response to ionizing radiation34. Additionally, TGFβ1 and other pro-inflammatory,
pro-fibrotic cytokines such as interferon, IL-1, IL-2, and tumour necrosis factor a (TNFa) inhibit
adipogenesis. Collectively, the sustained presence of these cytokines creates a microenvironment
that is hostile to the promotion of adipocytes. This compromises the success of tissue
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reconstruction.
Fibrosis in response to growth factors such as TGFβ1 may be focal or widespread, and also
contribute to tissue retraction, restriction of movement, and chronic pain that can be difficult to
manage34. Although TGFβ1 is clearly involved with the development of fibrosis, its numerous
effects on normal tissue function make it a poor target for therapy.

1.1.3 Effect on skin
Radiodermatitis, or radiation-induced skin reactions, have been recognized since the beginning of
the 20th century, and remains a significant clinical problem with no definitive evidence supporting
any one intervention in its prevention or treatment2,24. While many skin changes are minor and
reversible, radiation dermatitis remains a serious side effect, and may limit the duration of
treatment, dose delivered, and affect the quality of life of patients6.

1.1.3.1

Clinical assessment Scales

The ability to evaluate and quantify the severity of radiation-induced skin changes is important
from a clinical and research standpoint. This is especially important when evaluating potential
therapeutics to reduce such skin changes. There are scales described and regularly available for
the evaluation of radiation-induced dermatitis in humans and animals16,23.
In general, it has been suggested that further research is needed to develop a consensus reaction
assessment tool in order to provide management options for higher levels of skin toxicity in
sensitive areas16. A gold standard for clinically rating radiation skin injury does not exist, and
individualized skin assessment tool uptake and use is poor23. However, there are commonly used
scoring systems such as the National Institutes of Health Common Toxicity Criteria-Adverse
Event (CTCAE) and the Radiation Therapy Oncology Group (RTOG) toxicity scoring system3,12.
Other newer scoring scales include Douglas & Fowler (D&F), Oncology Nursing Society (ONS),
and Radiation Dermatitis Severity (RDS) scales8. It has been suggested that the use of more than
one scale should be considered when evaluating interventions to modulate radiation dermatitis due

5

to the limited evidence for support of these scales3.
The RTOG Acute Radiation Morbidity Scoring Criteria were developed in 1985 as a complement
to the Late Effects Scoring Criteria previously developed, and describes a scoring system 0-4 for
various organ tissues that may be affected by radiation (Supplemental Figure 1)12. Its original
purpose was to allow an international registry to be established to facilitate joint research studies.
Within model-based literature, the Kumar score is a scale that has been developed originally for
assessment of radiation injury in the hind leg of mice; it was used to provide a high level of detail
to cutaneous radiation injury including erythema, dry desquamation, moist desquamation,
ulceration, and full thickness injury (Supplemental Figure 2). This scale has also been used in a
study by Rodgers et al., in a guinea pig skin model to determine the dose-dependent response to
soft X-ray radiation to the dermis37.
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Supplemental Figure 1. Radiation Therapy Oncology Group (RTOG) acute radiation
morbidity scoring criteria12. This scale was originally developed to complement the Late Effects
Scoring Criteria to report toxicity in patients enrolled in studies between physicians, RTOG staff,
and the European Organization for Research and Treatment of Cancer (EORTC).
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Supplemental Figure 2. Kumar Scale38. A non-linear, semi-quantitative scale used to assess
skin damage; used in assessment of acute skin reactions of radiotherapy in mice.

8

1.1.4 Animal models
Animal models have been developed to study radiation-induced changes such as dermatitis and
ulcers. In general, the dosages studied in animals are comparatively higher than human doses. As
a reference, in humans, current National Comprehensive Cancer Network (NCCN) guidelines
recommend dosing regimens of 46-50 Gy in 23-25 fractions, or 40-42.5 Gy in 15-16 fractions.
Typical boost doses, recommended in patients at higher risk for recurrence, are 10-16 Gy in 4 to 8
fractions. These boost doses are relevant to patients who undergo breast-conserving therapy
(lumpectomy with whole breast irradiation), the primary breast local treatment for the majority
with Stage I and II disease39.
Ertekin et al. has described an animal model of radiotherapy-induced dermatitis while observing
the effects of zinc sulphate as a protective agent against radiotherapy; rats were given a one-time
dose of 30 Gy40. Takikawa et al. has developed a new animal model for intractable skin ulcers in
irradiated rats. Four groups of six rats each were given single doses of 10 Gy, 15 Gy, 20 Gy, and
30 Gy and observed for 24 weeks for presence or absence of epilation, depigmentation, erosion,
and ulcers amidst wounding with a punch biopsy over the radiation sites at various timepoints.
They found no visible changes in the skin in the 10 Gy group, depilation and depigmentation
present at 2 weeks in the 15 Gy group, minor erosions at 4 weeks in the 20 Gy group, and epilation
and depigmentation present at 2 weeks progressing to erosion and ulcers at 4 weeks in the 30 Gy
group41. Gu et al. have reported a different model of radiation-induced skin ulcer in rats, at 35-55
Gy resulting in a death rate of 20%42.
There is currently no literature on an animal model of radiation-induced changes concerning the
mammary fat pad; this will be the focus of this thesis.

1.1.5 Breast reconstruction
A prior history of radiation treatment affects the complication profile and available breast
reconstructive alternatives. There is an increasing number of patients receiving post-mastectomy
radiation therapy, and the timing and technique of breast reconstruction in this population is
controversial43.
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Alloplastic, or tissue expander and implant based reconstruction, is the most common method for
breast reconstruction after radiotherapy. Studies evaluating such two-stage breast reconstruction
in post-mastectomy radiation therapy patients with implant following tissue expander placement
reveal consistently high rates of acute and chronic complications such as capsular contractures and
poor aesthetic outcomes44. Ascherman et al. found higher complication rates, extrusion rates, and
asymmetry for irradiated breasts as compared to non-irradiated breasts in patients who underwent
two-stage implant-based reconstruction45. Interestingly, lower rates and severity of capsular
contracture has been described in a study by Cordeiro et al., where two-stage reconstruction was
completed before post-mastectomy radiation therapy46. Other types of implant-based
reconstruction along with an autologous flap such as transverse abdominis myocutaneous (TRAM)
and latissimus dorsi myocutaneous flap are associated with capsular contracture47.
Although there is consensus that autologous tissue-based reconstruction is preferable to breast
implants in an irradiated operative field, post-mastectomy radiation nevertheless has adverse
effects on outcomes in this population with respect to fat necrosis, vessel thrombosis, flap necrosis,
fibrosis, and flap contracture48–51. It has thus been suggested that autologous reconstruction be
delayed in those who will require post-mastectomy radiation therapy43,48–50,52.

1.2 Fat Quantification
Animal models involving transplantation of whole inguinal fat pads into mice scalp have been
used to study adipogenesis, graft survival, and differential contributions of graft-derived and hostderived cells53,54. In these cases, the ratio of harvested sample to body weight has been used to
evaluate the change in sample weight. More recently, Bahrami et al. have characterized fat content
in dorsal subcutaneous skin and fourth mammary fat pad, utilizing micro CT imaging,
morphometry, histology, RT-PCR and ELISA analyses of adipogenic gene expression to quantify
fat content55. Overall, there is very limited literature on the study of adipogenesis in an animal
model, and much fewer in the context of the mammary fat pad.
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1.3 Fat Grafting, Adipogenesis, and Fibrogenesis
The anti-fibrotic effects of fat transplants, in their reversal of radiation-induced damage, are
attributed to adipose-derived stem cells (ASCs) in the graft that produce adiponectin. Adiponectin
regulates myofibroblast and fibroblast differentiation56,57.
Adiponectin is a cytokine that is secreted predominantly by adipocytes. It has anti-fibrotic, antiinflammatory, anti-atherogenic and insulin-sensitizing effects58–60. Its receptors are found in
adipose tissue, skeletal tissue, and liver61. It is upregulated when pre-adipocytes differentiate into
mature adipocytes58,61,62, and depleted in lipodystrophy in animal studies60.
Mature adipocytes reduce tissue rigidity by altering the mechanical properties of connective tissue,
thus sustaining the differentiation and survival of myofibroblasts. Fibrosis is characterized by
excessive Collagen-1 to Collagen-3 ratio63. We also know that TGFß1, a fibrogenic cytokine,
inhibits adipogenesis64. Fibrogenesis is increased when there is loss of adipocyte function due to
reduced expression of anti-fibrotic adipokines such as adiponectin65. Technologies that target this
pathway, effectively promoting adipogenesis while reducing fibrosis in breast tissue would
improve fat take and reduce side effects of radiotherapy.
The optimal properties of fat grafting mentioned above result in part from the ability of mature
adipocytes to reduce tissue rigidity by altering the mechanical properties of connective tissue –
thus blocking the differentiation and survival of myofibroblasts – and from anti-fibrotic functions
of adipokines such as adiponectin and leptin. Therefore, development of therapies that can enhance
the long-term survival of adipocyte progenitor cells would greatly benefit successful
reconstruction of breast tissue in cancer patients. One microenvironmental factor that affects preadipocyte survival and differentiation, and fibrosis is the tissue polysaccharide, hyaluronan.

1.4 Hyaluronan
Hyaluronan (or hyaluronic acid, HA) is a carbohydrate in the glycosaminoglycan family in
mammalian tissues first discovered in bovine vitrous humour of the eye in 193466. It is a major
extracellular matrix (ECM) component, particularly in skin, and consists of repeating polymeric
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disaccharides D-glucuronic acid and N-acetyl-D-glucosamine linked by alternating glucurinidic
ß(1,3) and ß(1,4) bonds29,67,68. It plays an important role in tissue repair, displays antioxidant
properties, and promotes cell migration and proliferation69,70. It is also well known that when HA
is fragmented it functions as a molecule that transmits signals and is involved in cell adhesion,
motility, growth, and differentiation71. Notably it is important for maintaining tissue homeostasis
and regulating inflammation, fibrosis and stem cell renewal in damaged tissues29,72,73.
In fetal skin, HA remains in its native high molecular weight form (HMWHA), and attenuates
inflammation and fibroplasia74–77. It also provides a hydrated, anti-inflammatory and cytokine rich
microenvironment for various skin progenitor cells that maintains their “stemness” and protects
them from ionizing radiation-induced DNA damage. In injured adult skin, HA is degraded into
low molecular fragments through hyaluronidases and reactive oxygen/nitrogen species
(ROS/NOS)73,78–80. Rapid alterations in hyaluronan production and polymer size within tissues are
among the earliest changes that can be detected following injury from exposure to ionizing
radiation29,80–83. These low molecular weight fragments are well characterized to stimulate
inflammation, and if chronically present, result in tissue destruction from uncontrolled fibrosis84.
As well, HA promotes the trafficking and differentiation of progenitor cells in particular
mesenchymal lineages73,78,85. Notably, HMWHA supports survival, proliferation, and
differentiation

of

pre-adipocytes,

while

fragmentation

of

HA

suppresses

adipocyte

maturation55,86,87.
HA fragments mediate their pro-inflammatory and pro-fibrotic effects through interactions with
various cell-surface receptors. CD44 is the major constitutively expressed HA receptor of the
epidermis82. It is also required for subcutaneous adipogenesis, and is implicated in the stimulation
of aggregation, proliferation, migration, and angiogenesis71,88,89. The receptor of hyaluronan
mediated motility (RHAMM) is another cell surface receptor and CD44 binding partner that is
expressed during tissue inflammation and repair, and will be a focus of this thesis. Other additional
HA cell surface receptors include lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1), a
homologue of CD44, and toll-like receptor 2 and 4 (TLR2,4)74,90. Phosphoinositide 3kinase/protein kinase B (PI3 kinase/AKT), and mitogen-activated protein kinase kinase
1/extracellular signal-regulated kinase 1,2 (MEK1/ERK1,2) are downstream pathways that are
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activated by these receptors74. Importantly, the activation of signaling cascades through RAS-MAP
(ERK) kinase regulates mesenchymal differentiation required for tissue injury repair91,92. This will
be further elaborated upon below.

1.4.1 ERK1
HA receptors such as CD44, RHAMM, and TLR2,4 as mentioned detect and bind to HA
fragments, collectively controlling the activation of MAP kinase signaling networks. Ultimately
this plays a part in regulating the migration, proliferation, and differentiation of progenitor cells
into specific mesenchymal lineages to maintain tissue homeostasis and repair tissues. It is known
that fibrosis and adipogenesis originate from a common mesenchymal progenitor93, with MAP
kinase and ERK1 pivotal for substantial tissue formation. ERK1 is required for the clonal
expansion of mesenchymal progenitor cells into proliferating pre-adipocytes (Figure 1).
The importance of the MAP kinase pathway in adipogenesis is demonstrated by the report that
ERK1-/- mice have fewer adipocytes and reduced adiposity than their wildtype (WT) counterparts
due to the key requirement of ERK1 in clonal expansion of pre-adipocytes. In order to transition
from pre-adipocytes into mature adipocytes, the progenitors must respond to differentiating factors
present in their microenvironment that activate PPARg, a master adipogenic transcription factor.
ERK inactivates PPARg. Connective tissue growth factor (CTGF), one of ERK’s downstream
transcription targets also inhibits PPARg expression. Sustained ERK activity thus promotes
fibrogenesis, while inhibition of ERK1 kinase promotes adipogenic differentiation of the expanded
pre-adipocytes.
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Figure 1. Model of the roles of ERK activity and RHAMM in mesenchymal progenitor
cell differentiation into adipocytes. This model highlights the key role of ERK1,2 activity
in the clonal expansion of pre-adipocytes and predicts that expanded pre-adipocytes express
RHAMM which sustains ERK activation. Together these suppress the differentiation of preadipocytes to mature adipocytes. Either loss or function blocking of RHAMM and ERK
activity results in the differentiation of expanded pre-adipocytes into mature adipocytes.
Figure from the Turley Lab, (unpublished).
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1.5 RHAMM
RHAMM (gene name HMMR) is a regulator of ERK activity. It is a multifunctional cell surface
and intracellular protein, and is located on the cytoskeleton, in mitochondria, and in cell nucleus94–
96

. It is not constitutively expressed in most homeostatic tissues, with the exception of some type

of progenitor cells, but is transiently expressed in tissues repairing an injury. Although it is
secreted, it does not contain a signal peptide for export through the golgi apparatus or endoplasmic
reticulum. Thus, it resembles proteins such as basic fibroblast growth factor (BFGF), Human
immunodeficiency virus trans-activator of transcription (HIV Tat) protein, heat shock proteins
(HSPs), the homeobox protein engrailed (EN), and epimorphin97–99 in its ability to be
unconventionally exported through the plasma membrane. The binding of extracellular hyaluronan
to secreted RHAMM, which couples with CD44, plays a key role in activating signal cascades
MAP kinases, ERK1,2. This occurs in response to mesenchymal growth factors and receptors such
as PDGFß and PDGFR. Intracellular RHAMM is a regulator of ERK activity, and co-associated
with approximately 20% of total cellular ERK1 kinase100.
Activation of this CD44 signaling pathway thus promotes fibrogenesis and myofibroblast
differentiation and blocks PPARg and adipogenesis. Intracellular RHAMM performs adapter
protein functions that include coupling ERK to its upstream activators. It also targets these to its
downstream substrates in the nucleus. These intracellular RHAMM/ERK1,2 signaling complexes
participate in expression of a subset of fibrogenic genes, some of which suppress adipogenesis.
HA is the major RHAMM ligand that plays a role in controlling adipogenesis and fibrosis; it is
particularly enriched in mesenchymal progenitor niches.
Unlike ERK, RHAMM does not appear to be essential for clonal expansion of pre-adipocytes,
knockout of HMMR (protein product: RHAMM) has resulted in an increase in adipose tissue. In
other words, if RHAMM were required for pre-adipocyte clonal expansion like ERK1 is, adipose
tissue formation would be decreased when it is lost. Its expression instead directs the
differentiation of progenitors towards myofibroblasts and dermal fibroblast phenotypes, and
blocks differentiation of pre-adipocytes into mature adipocytes.
Unique properties of RHAMM that make it a better therapeutic target than ERK1 for controlling
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fibrogenesis and adipogenesis include its restricted expression in most homeostatic cell types. It is
also limited to these progenitor cells. This is predictive of a good safety profile, alongside its dual
functions of myofibroblast-promotion and adipocyte-suppression.

1.5.1 RHAMM-based peptides
The low molecular weight HA fragments that promote myofibroblasts and inhibit adipogenesis
bind to extracellular RHAMM and CD44. These interactions, as mentioned, activates the RASMAP kinase pathway and stimulates the formation of intracellular RHAMM/ERK that are required
for expression of key fibrogenic genes and suppression of PPARg. Blocking the binding of HA
fragments to these receptors would thus decrease fibrogenesis and promote adipogenesis via
relieving suppression of PPARg.
RHAMM mimetic peptides have recently been developed that perform such functions. These
peptides fall into two categories: those that act either by directly binding to HA fragment sizes that
are typically generated in small amounts during tissue injury (Kd=10nM) or by binding directly to
RHAMM to block its ability to associate with HA fragments. One of these peptides, NPI-110 has
been reported to promote adipogenesis by releasing the RHAMM-mediated block on PPARg
expression. This and other adipogenic RHAMM peptides were identified by screening for an
ability to promote adipogenesis in culture assays using bone marrow mesenchymal stem cells,
mouse pre-adipocyte cell lines, and primary human subcutaneous pre-adipocytes. NPI-110, or
644

KLKDENSQLKSEVSK was a peptide that was selected as the most effective in promoting

adipocyte differentiation in bone marrow mesenchymal cells, human and mouse pre-adipocytes in
culture55.
NPI-110 and similar peptides appear to act specifically on RHAMM regulated pathways since they
do not affect these functions in RHAMM-/- cells. The limited expression of RHAMM in
homeostatic tissues predicts a good safety profile, and since NPI-110 directly blocks fibrosis and
promotes adipogenesis, we predicted it would be an efficacious therapy for reducing radiofibrosis
and for creating a breast tissue microenvironment more favorable to the survival of grafted fat.

16

Our lab has shown that NPI-110 significantly blunted mRNA expression of many fibrogenic and
pro-inflammatory genes expressed by fibroblasts and macrophages when cultured macrophages
and mesenchymal cells stimulated with TLR-4 agonists or TGFß1 (Figure 2). In studies in an
animal model of bleomycin-induced scleroderma, which usually is associated with a TGFß1 driven
increase in fibrosis and loss of adipose tissue, NPI-110 has a reduction in mRNA expression of
pro-fibrosis genes and blunted loss of adipocytes101.

ERK1, which are required for clonal expansion of mesenchymal progenitor cells into proliferating
pre-adipocytes, we recall inhibits PPARg. Blocking RHAMM, a regulator of the ERK pathway
with these peptides would release inhibition of pre-adipocytes and allow it to differentiate into
mature adipocytes as seen below (Figure 3).

Recall that the activation of intracellular RHAMM/ERK1,2 complexes as a result of extracellular
RHAMM activation would result in the promotion of myofibroblasts, PPARg inhibition, and
adipogenesis suppression. RHAMM mimetic peptides would bind with the hyaluronan fragments,
halting hyaluronan fragments from binding with the extracellular RHAMM, thus preventing the
differentiation of myofibroblasts, and prevent the inactivation of PPARg and promote adipocyte
differentiation (Figure 4).
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FIBROBLASTS

MACROPHAGES

TABLE 1. RHAMM PEPTIDES SUPPRESS EXPRESSION OF RHAMM
REGULATED PRO-FIBROSIS GENES
GENE NAME

FUNCTION

% INHIBITION BY RHAMM
PEPTIDES

Il1α

Pro-inﬂammatory cytokine

37

IL17

Pro-inﬂammatory cytokine

89

CCL1, 5 & 25

White cell chemotac@c
factors

64, 79 &64

TNFα

Immune regulator, promotes
inﬂamma@on

67

TGFβ-1

Master ﬁbrosis promoter

50

CTGF

TGFβ-1 target gene, promotes
@ssue ﬁbrosis and blocks
adipogenesis

82%

COL3a1

Contributes to collagen
ﬁbrillogenesis during @ssue
ﬁbrosis

90%

MMP1

Metalloproteinase
contributes to extracellular
matrix remodelling during
@ssue ﬁbrosis

90%

GREM 1

TGFβ-1 target that promotes
@ssue ﬁbrosis and blocks
adipogenesis

74%

Figure 2. RHAMM peptides suppress expression of RHAMM regulated profibrosis genes. Mouse macrophage and dermal fibroblast lines were stimulated
with a TLR4 agonist and TGFß1 respectively with and without the RHAMM
peptide mimetic; mRNA was isolated and fibrosis PCR arrays performed. The
mRNA expression of genes that were significantly (p<.05) reduced are listed in the
table. Adapted from unpublished data from the Turley lab.

18

Figure 3. The MAP kinase ERK1 is required for the clonal expansion of
mesenchymal progenitor cells into proliferating pre-adipocytes but suppresses
maturation into adipocyte in the presence of RHAMM. Proliferating preadipocytes express RHAMM, which regulates localization and transcriptional
targets of ERK1 resulting in suppression of the mast adipogenic transcription
factor, PPARg to prevent maturation of pre-adipocytes into mature adipocytes.
RHAMM mimetic peptides block this RHAMM function and release inhibition of
PPARg to permit adipocyte maturation. Figure from the Turley Lab (unpublished).
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Figure 4. Mechanistic model of RHAMM mimetic peptide inhibiting fibrogenesis
and promoting adipogenesis. A. Hyaluronan fragments bind to extracellular
RHAMM expressed on adipose derived stem cells resulting in the formation of a
complex with CD44 and growth actor/receptors. This activates the RAS-MAP kinase
pathway and formation of intracellular RHAMM/ERK signaling complexes which
promote differentiation into myofobroblasts. These ERK complexes phosphorylate
and inactivate the master adipogenic transcription factor PPARg, blocking
adipogenesis. B. RHAMM mimetic peptides bind to hyaluronan fragments, which
prevents differentiation of myofibroblasts and inactivation of PPARg and thus promote
adipocyte differentiation. Figure from the Turley Lab (unpublished).
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1.6 Identifying the problem
Dermal fibrosis as a result from radiotherapy is a challenge for breast reconstruction. Fat grafting
has emerged as a technique that can reverse some late radiotherapy changes, as well correct contour
abnormalities. RHAMM, a receptor for HA, has been identified as a potential target for tissue
fibrosis, as it is involved in the pathways that leads to increased fibrogenic and decreased
adipogenic gene expression. Dr. Turley’s laboratory has developed RHAMM mimetic peptides
that have been shown effectively decrease fibrogenesis and promote adipogenesis in vivo. We
aimed to study the effects of this peptide, in a novel rat model of radiation-induced mammary fat
pad fibrosis. We propose a novel approach for reducing radiotherapy associated changes and
promoting adipogenesis with this peptide, as a potential adjunct to fat grafting in breast
reconstruction outcomes following radiotherapy.
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2

Thesis Objectives and Aims

The hypothesis of the study is thus that the injection of RHAMM mimetic (NPI-110) peptides
decrease fibrosis and increase adipogenesis in a rat model of radiation induced mammary fat pad
fibrosis. The three primary objectives of the thesis are outlined below.
Objective 1: Create a rodent model of radiation-induced mammary fat pad fibrosis
The creation of a rat model of radiation-induced mammary fat pad fibrosis will serve as a basis for
observing the effects of the peptide in such a setting. It will also serve as a basis for future fat
transplantation studies.
Aim 1: Following a one-time radiation dose of 26 Gy in bilateral fourth mammary fat pads
of rats, perform clinical assessments via visual skin assessments with two grading scales
previously described (Kumar, RTOG).
Aim 2: Following a one-time radiation dose of 26 Gy in bilateral fourth mammary fat pads
of rats, use paraffin processed mammary fat pad specimens to quantify the amount of
staining for immunohistochemistry markers of fibrosis (TGFb1 and Picrosirius Red).
Aim 3: Following a one-time radiation dose of 26 Gy in bilateral fourth mammary fat pads
of rats, use mammary fat pad tissues to quantify the amount of expression of fibrotic
markers (TGFb1, ratio of Collagen-1 and Collagen-3) with quantitative PCR.
Objective 2: Examine the effect of RHAMM mimetic peptides on fibrosis in irradiated
mammary fat pads
RHAMM is implicated in the fibrotic pathway as described above. The thesis aims to examine the
effect of RHAMM peptide mimetics on fibrosis in the context of a rat model of mammary fat pad
fibrosis.
Aim 1: Using paraffin processed mammary fat pad specimens, quantify the amount of
staining for immunohistochemistry markers of fibrosis (TGFb1 and Picrosirius Red).
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Aim 2: Using mammary fat pad tissues, quantify the amount of expression of fibrotic
markers (TGFb1, ratio of Collagen-1 and Collagen-3) with quantitative PCR.

Objective 3: Examine the effect of RHAMM mimetic peptides on adipogenesis in irradiated
mammary fat pads
RHAMM is implicated in the adipogenesis pathway as described above. The thesis aims to
examine the effect of RHAMM mimetic peptides on adipogenesis in the context of a rat model of
mammary fat pad fibrosis.

Aim 1: Using high frequency ultrasound, quantify the amount of adipogenesis through
measurements of mammary fat pad thickness and volume.
Aim 2: Using paraffin processed mammary fat pad specimens, quantify the amount of
staining for immunohistochemistry marker of adipogenesis (adiponectin).
Aim 3: Using mammary fat pad tissues, quantify the amount of expression of adipogenic
markers (PPARg and adiponectin) with quantitative PCR.
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3

Methods

All experiments were approved and compliant with the standard operating protocols of the Animal
Use Subcommittee (Protocol # 2009-060) at Western University in London, Ontario, Canada.

3.1 Peptide Injection Formulation
Patented (through World Discoveries, Lawson Health Research Institute) function blocking
RHAMM peptides (peptide mimetics)

644

KLKDENSQLKSEVSK (denoted NPI-110) were

synthesized and purified to >95% purity (ProSci and gift of Dr. L. Luyt, Western University and
Novare Pharmaceuticals Inc). Peptides dissolved in PBS (2 mg/ml) were sterilized by filtration
through 0.22 µm filter at a concentration of 2 mg/ml. This was then mixed 1:1 with hyaluronic
acid (Orthovisc, Anika Therapeutics, Bedford, MA) for a final concentration of 1 mg/ml. A vehicle
mixture of 1:1 of PBS (2 mg/ml) and Orthovisc was formulated without the peptide mixed in for
the control group.

3.2 Rat Experiments
Animal work performed at London Health Sciences Centre, London Regional Cancer Program,
and Robarts Research Institute conformed to animal use protocol #2009-060.

3.2.1 Preliminary Experiments
Preliminary experiments involving four retired breeder female CD (Charles River) rats were used
to determine clinically detectable doses of radiation from a fibrosis standpoint. Rats were irradiated
at two doses using a modified procedure of Jourdan et al. to determine clinically detectable doses
of radiation fibrosis102. The rats were 6 to 12 months of age. Rats were caged in pairs in a
temperature-controlled room with 12 hour light/dark cycle, and fed a standard rat chow diet. One
rat was not irradiated and served as a control. The other three rats received a high dose of radiation
in the left third mammary fat pad, and a lower dose in the left fourth mammary fat pad. The right
third and fourth sets were not irradiated.
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Radiation was administered to three rats with Therapax-150 (T-150) unit to achieve a focused
radiation beam of 2.37 Gy/min (probe diameter: 1 cm). Animals were induced and maintained
with isofluorane gas in a clear plastic chamber by nose cone during radiation. Hair over the
abdomen overlying the third and fourth set of nipples bilaterally were trimmed with a razor in a 2
cm diameter area. Rats were positioned supine, with laboratory tape used to secure and position
the rat in a rotated fashion so that the fat pad and overlying skin were the main target of the
radiation probe. In other words, the underlying organs were spared from radiation. A high dose of
26 Gy over 11.2 minutes was given to the left third mammary fat pad. A low dose of 13 Gy over
5.6 minutes was given to the left fourth mammary fat pad.
Animals were housed in Health Sciences Animal Research Facility, Western University for 3
weeks following radiation and provided with water and standard rat diet. Animals were euthanized
at 3 weeks. The mammary fat pads were dissected and fixed in 4% paraformaldehyde (pH 7.4;
Sigma-Aldrich, St. Louis, Missouri) for paraffin processing for histology.

3.2.2 Main Experiment: Animals
Twenty retired breeder female CD (Charles River) rats were used for the following experiments.
Rats were caged in pairs in a temperature-controlled room with 12 hour light/dark cycles, and fed
a standard diet. The fourth set of mammary fat pads were chosen because of its ease of
identification, relative distinction from neighbouring fat pads, and previous use in literature55.
There were four treatment groups with 5 rats each, with the designations outlined in Table 1:
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Group

Radiation

Peptide

-/- (Control)

No

No

-/p

No

Yes

r/-

Yes

No

r/p

Yes

Yes

Table 1. Breakdown of treatment groups
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3.2.2.1

Radiation

Radiation was administered in radiation treated groups using a Therapax-150 (T-150) unit to
achieve a focused radiation beam of 2.37 Gy/min (probe diameter: 1 cm). Animals were induced
and maintained with isofluorane by nose cone during radiation. Hair over the fourth set of nipples
were trimmed with a razor in a 2 cm diameter area. Rats were positioned supine, with laboratory
tape used to secure and position the rat in a rotated fashion so that the fat pad and overlying skin
were the main target of the radiation probe in a manner similar to that mentioned above. Animals
in the radiation group received a single dose of 26 Gy; 2.37 Gy over 11.2 minutes. Both mammary
fat pads in the fourth set of nipples were irradiated in rats in the radiation-treated groups (n=10).

3.2.2.2

Peptide Injection

Animals in the -/p and r/p groups received a single injection of 100 µg peptide in vehicle
formulation (1 mg/ml) as described above in the mammary fat pads of the fourth sets of nipples.
Animals in the non-peptide treated group received the same volume of injection of the vehicle
formulation without the peptide mixture (100 µl). This was performed under direct visualization
under ultrasound on Day 0 as described below (Supplemental Figure 3).

27

Supplemental Figure 3. Ultrasound images of nipple pre (left) and post (right) injection of
peptide or vehicle
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3.2.2.3

High Frequency Ultrasound

Ultrasound experiments were carried out at Robarts Research Institute in the James Lacefield lab.
Animals were induced and maintained with isofluorane by nose cone during ultrasound. Rats were
placed supine on a heated platform set to 35°C. A motorized razor was used to remove hair over a
2 x 5 cm area overlying the fourth set of nipples on Day 0, followed by Q-tip® assisted application
of Nair®. This was done to ensure clear images via ultrasound and only on the Day 0 to avoid
further irritation of the skin. Subsequent ultrasound images taken at Day 7, 14, and 21 were
augmented by motorized razor trimming of hair regrowth, and not by chemical de-epilation to
reduce irritation to skin that may confound skin assessments.
A Vevo2100 ultrasound Imaging System (VisualSonics, Toronto, ON) equipped with a MS-550D
transducer was used for high frequency ultrasound data. The imaging resolution was 40 µm (axial)
and 80 µl (lateral). Image acquisition was transmitted at 40 MHz, with an image width of 14.08
mm, and depth of 15 mm.
A thin layer of ultrasound gel (Aquasonic 100, Parker Laboratories, Fairfield, NJ) was applied
over the transducer and 2 x 5 cm area over the nipple of interest. Care was taken to minimize the
amount of bubbles in the gel so as not to interfere with quality of image acquisition. The transducer
was then hooked into an upright ultrasound stand. Image acquisition was set to B mode, a twodimensional ultrasound image display composed of bright dots, and centered on the nipple. This
scanning process for 3D image acquisition utilized a step size of 0.083 mm, with a total distance
of 44 mm along the length of the rat centered on the nipple.
On Day 0, after the scanning was completed, the transducer was once again centered along the
nipple. A 27 gauge needle was used to inject a one-time 100 µl vehicle formulation with (-/p and
r/-) or without peptide (-/- and r/-), depending on the treatment group under the fourth nipple into
the mammary fat pad. The transducer was removed, and gel wiped off at this point. Photographs
were then taken at this time, while supine on the heated platform, with interest in the skin condition
over the fourth nipple set. Photographs were also taken in a similar fashion on proceeding days of
scanning on Day 7, 14, and 21. It should be noted that only two rats per group were scanned on
Day 7.
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3.2.2.4

Euthanization and Dissection

After photographs were taken and ultrasound imaging performed on Day 21 under general
anesthesia, rats were euthanized the same day in Western University animal facilities in a carbon
dioxide (CO2) chamber.
Rats were secured to a Styrofoam board with 18 gauge needles. A skin marker was used to plan
the incisions, and a 15-blade used to make a longitudinal midline incision from the xyphoid process
down to the pubis, and transversely to the mid-axillary line at these landmarks. Dissection was
carried along an alveolar plane, deep to the level of the mammary fat pad and superficial to the
parietal peritoneum. The fourth mammary fat pad was identified visually, by a deep yellow tissue
with an adipose-tissue appearance. For consistency, the area of dissection was marked out by a
skin marker that included the subcutaneous tissue up to the level of the xyphoid process for the
cephalad border, the dorsal border of the fat pad as the medial border, the most ventral-medial
border of the fat pad as the lateral border, and just proximal to where a blood vessel to the fourth
mammary fat pad emerges as the caudal border of the fat pad (Supplemental Figure 4). Dissection
of the subcutaneous tissue including the mammary fat pad was carried down to the plane between
dermis and subcutaneous fat. Sections were subsequently weighed. An additional fat pad was taken
as an intra-rat control in each rat, of a single fat pad in the 5th nipple set.
Two rats in each treatment group were planned for immunohistochemistry, and these fat pads were
placed in cassettes and 4% paraformaldehyde at 4°in anticipation of fixing and sectioning. Three
rats in each treatment group were planned for qPCR experiments, and were thus placed in
Eppendorf tubes, snap frozen, and kept at -80°C.
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Supplemental Figure 4. Markings for dissection of 4th mammary fat pad
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3.3 Effect of radiation and peptide on fibrosis
3.3.1 Immunohistochemistry – H&E, Masson’s Trichrome
Fat pads were processed for paraffin histology slides. 4 µm sections were cut using a Microm HM
200 Ergostar Microtome (GMI; Ramsey, Minnesota, USA). Sections were stained with
hematoxylin and eosin (H&E) to confirm the presence of subcutaneous adipose tissue. Adipocytes
were identified as large vacuoles on imaging and visual inspection as paraffin processing removed
the lipid content. Sections were also stained with Masson’s Trichrome (Sigma-Aldrich, St. Louis,
Missouri).

3.3.1.1

TGFβ1

Fat pads from the rats were fixed and processed for paraffin embedded histology slides. Antigen
retrieval was performed using Antigen 2100 Retriever (Aptum Biologics Ltd, Southampton,
UK). De-paraffinized tissue sections were incubated with Anti-TGFb1 monoclonal antibody (1:50
dilution, Abcam ab92486) overnight at 4°C. The tissue sections were washed in PBS and then
incubated with an anti-rabbit secondary antibody conjugated to horseradish peroxidase (1:500
dilution, Abcam) for 1 hour at room temperature. Colorimetric detection was then performed using
nickel 3,3’-diaminobenzidine (DAB; 0.15 mg/ml in 0.03% H2O2; Sigma). Sections were
counterstained with H&E. The negative control was isotype matched non-immune IgGg used in
place of the anti-adiponectin antibody. From each experimental group, specimens were obtained
from two rats. For each rat, both left and right mammary fat pads were analyzed.

3.3.1.2

TGFβ1 Quantification

Using Aperio© ImageScope (Aperio ePathology Solutions; http://www.aperio.com/), a total of
three images per mammary fat pad specimen were taken at 10x magnification. Specimens that
were too small, damaged, or ripped were excluded. The Aperio image was saved and transferred
to ImageJ 1.47 software.
In ImageJ 1.47, areas that were predominately fibrosis and ductal tissue were preserved while
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adipocytes were excluded from the quantification. The ductal tissue was traced by hand via Wacom
Intuos 4 (Portland, OR), and the adipocytes were erased. The isolated tissue was saved as a new
image.
Next, the new image was de-convoluted under the ‘H DAB’ setting, allowing ImageJ to separate
the different colour channels to isolate the blue staining from hematoxylin and the positive brown
staining from TGFb1 antibody. On the brown channel, the image was adjusted at a threshold of
215 units as a conservative assessment for identifying positively stained cells, and the blue channel
was adjusted at a threshold of 225 units as a conservative assessment for identifying the number
of total stained pixels.

To determine the ratio of hematoxylin staining to TGFb1 antibody staining, the ratio of pixels of
the isolated brown to blue channels was taken on ImageJ 1.47. The channels were analyzed using
ImageJ 1.47 and the histograms were used to obtain pixel counts for both channels. The individual
pixel counts were recorded, and the ratio was calculated. A higher ratio of brown to blue staining
would demonstrate greater TGFb1 staining in those tissues, and was expressed as a percentage.
Five images were analyzed per slide, with two slides per rat.

3.3.1.3

Picrosirius Red Staining

Paraffin processed tissue sections of skin were stained for collagen using Picrosirius Red staining
Kit (Cat# 2490-250, Polysciences, Warrington, PA) with the help of the Molecular Pathology Lab
at Robarts Research Institute. Again, two sections per rat (right and left fat pads) and two rats per
group were stained. Under polarized light, Picrosirius Red Staining is able to comment on collagen
deposition and bundling103. Thus, expression of red, or denser bundling in the tissue is associated
with greater fibrosis. Conversely, blue reflects a lower density of collagen bundling.
Abrio 2.2 (Cri, Woburn, MA, USA) software was used for image acquisition. Slides were
examined under polarized light, and five randomized images at 40.0X magnification were taken
of each slide of areas that were composed primarily of adipocytes. Five additional images at 40.0X
magnification were taken in a randomized fashion of areas that were composed primarily of ductal
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tissue. Image acquisition and analysis was performed by a blinded assessor. Images were saved in
Grayscale and Pseudocolour format. The intensity range for the live image acquisition was set at
99.6 for each image. Analysis was carried out in Photoshop CC (Adobe, Mountain View,
California, USA).
For slides containing ductal tissue and surrounding fibrosis, the ducts were isolated by manually
cropping out adipocyte tissue that surrounded the ductal tissue. The total pixel count of this area
was then recorded. Expression was red and blue was then isolated in the method described above.
In addition, a duplicate image was further cropped to reveal only the ducts, which were exempt
from collagen deposition.
Expression of extent of collagen deposition was thus examined by observing the amount of red
expression, with respect to area and corresponding blue expression. The total number of red pixels
multiplied by mean value (in other words, intensity), was used to provide a measure of absolute
red expression. This was then compared to total pixel area when observing adipocytes.
Red expression in ductal tissues = (red pixels x red mean)/(pixels of area with adipocytes – ductal
area)
Red:blue expression = (Red pixels x red mean)/ (blue pixels x blue mean)

3.3.2 qPCR
Fat pads were dissected in method above from rats and snap-frozen. Frozen mammary fat pads
were thawed in Trizol (Thermo-Fisher, Waltham, MA) and homogenized on ice. Fat pads were
separated at initial dissection into nipple and peripheral samples. These samples were weighed and
RNA combined proportionally according to fat pad mass after extraction so they could be directly
compared with whole samples.
RNA was extracted using a phenol–chloroform procedure. Homogenates in Trizol were divided
into 1 mL tubes. 200 µL chloroform was added and samples were mixed and centrifuged in a tabletop centrifuge at 4°C for 15 minutes at 12,000 rpm. The top aqueous phase was transferred to a
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new tube. RNA was precipitated by adding one volume of isopropanol and washed three times
with cold ethanol then dried in the fume hood and re-suspended in 20 µL nuclease-free water.
RNA was quantitated by spectroscopy (NanoDrop, Thermo-Fisher).
Reverse transcription was performed with SuperScript VILO cDNA Master Mix (Thermo-Fisher).
Reactions consisting of 1000 ng RNA, 4 µL Master Mix, and sufficient nuclease-free water to
make the reaction up to 20 µL were prepared and incubated according to the kit manual. The
resulting cDNA was diluted 1:10 in nuclease-free water.
Quantitative PCR was performed with SsoAdvanced SYBR Green Supermix (Bio-Rad, Hercules,
CA) using 10 µL master mix with 1 µL of forward and 1 µL reverse primer, each at 10 ng/µL, and
8 µL of diluted cDNA per reaction. Primer sequences are available in Supplemental Table 1. qPCR
was run on a Mx3000P system (Agilent Technologies, Santa Clara, CA) with 40 cycles at an
annealing temperature of 60°C. Specificity of amplification was confirmed with melting curve
analysis. Expression was calculated using the 2−∆∆Ct method relative to Gapdh expression and
normalized to expression in the non-irradiated, untreated samples. Please note that adipogenic
markers pertaining to section 3.4 are included in Table 2 below:

3.3.3 Skin Assessments
Photographs of the rats were taken at Day 0, 7, 14, and 21 after ultrasound gel was wiped off as
described above. Images of all the rats in different groups over the time points were then uploaded
onto Qualtrics, an online survey software tool (Provos, Utah, USA) and randomized. A modified
version of previously described skin assessment scales, Kumar and RTOG, accompanied this
online survey to serve as a scoring guide (Supplemental Figure 5). The survey was then sent to a
staff physician with expertise on skin changes associated with radiation damage, as well as two
resident physicians in plastic surgery. The reviewers were blinded to the treatment groups and day
of treatment.
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Target
Tgfb1
Col1a1
Col3a1
Adipoq
Pparg
Perilipin
Gapdh

Forward primer
ATGACATGAACCGACCCTTC
GAGCGGAGAGTACTGGATCG
TGATGGGATCCAATGAGGGAGA
TAAGGGTGACCCAGGAGATG
AGAGCTGACCCAATGGTTGC
TGCAAFCATTCTGACAAGG
CTCATGACCACAGTCCATGC

Reverse primer
ACTTCCAACCCAGGTCCTTC
TACTCGAACGGGAATCCATC
GAGTCTCATGGCCTTGCGTGTTT
GGAACATTGGGGACAGTGAC
AAGGCTCTTCATGTGGCCTG
GGAGCCTTCTGCATCTTTTG
TTCAGCTCTGGGATGACCTT

Table 2. qPCR Primer Sequences for fibrotic, adipogenic markers and housekeeping gene
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Supplemental Figure 5. A. Kumar scale B. RTOG scale
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3.4 Effect of peptide on adipogenesis
Immunohistochemical studies and qPCR studies for adipogenic markers were performed as
previously described in section 3.3.

3.4.1 Immunohistochemistry
Fat pads were processed in same method as mentioned above for TGFb1. From each experimental
group, specimens were obtained from two rats. For each rat, both left and right mammary fat pads
were analyzed.

3.4.1.1

Adiponectin

Paraffin-embedded sections were de-paraffinized in xylene and rehydrated in a graded ethanol
series. Antigen retrieval was performed with sections in a 0.01 M aqueous sodium citrate buffer
(pH 6.0) using a microwave oven, with care taken to heat the tissues to just below boiling so as
not to disturb the delicate nature of the highly fatty tissues. Following this, sections were washed
in 1x PBS three times for 5 minutes each and treated with 3.0% hydrogen peroxide for 10 minutes.
After a further wash of 1x PBS, tissues were blocked with 3.0% BSA for 1 hour at 4 °C . The
tissue sections were then incubated with anti-adiponectin monoclonal antibody (dilution 1:200,
Abcam, ab22554) in 3% BSA overnight at 4°C. The negative control was isotype matched nonimmune IgG used in place of the anti-adiponectin antibody. Sections were washed in PBS then
incubated with Goat anti-mouse secondary IgG (dilution 1:500, Dako, E3044) at 2 µg/ml for 2 hr
at room temperature. After washing, sections were incubated in streptavidin-horseradish
peroxidase (dilution 1:2000 Abcam, ab7403) for 30 min at room temperature. Staining was
visualized with diaminobenzidine (DAB) according to kit instructions (DAKO Liquid DAB +
Substrate Chromogen System); 35 seconds was necessary for colour development. Sections were
counterstained in hematoxylin and washed with distilled water. An ascending ethanol series and
xylene wash were performed before Cytoseal 60 (Thermoscientific) was applied, followed by a
glass cover slip application.
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3.4.1.2

Adiponectin Quantification

Images of mammary fat pads for quantification were obtained using Aperio© ImageScope (Aperio
ePathology Solutions; http://www.aperio.com/). A total of five images per specimen were taken at
10.0X magnification, one in each of four quadrants and one in the center region. Each Aperio
image was saved and transferred to ImageJ 1.47.
In ImageJ 1.47, adipocytes were manually excluded, leaving only the glands and surrounding
stroma to be analyzed. The image of the now isolated tissue was saved. Next, the image was
deconvoluted under the ‘H DAB’ setting, again similar to the process for TGFb1. The brown
deconvoluted image was set to a threshold pixel range of 165 units, to set a conservative
assessment for identifying positively stained cells, and the blue channel was adjusted at a threshold
of 240 units as a conservative measurement for identifying the number of total blue pixels.
The ratio of positively stained brown cells to blue cells was used to determine the strength of
adiponectin staining within each image. This ratio was compared to the ratio from the image of
the entire specimen, in order to determine whether there was increased adiponectin staining near
the glands. Three images were analyzed per slide, with two slides per rat.

3.4.2 Volume Assessment
3.4.2.1

Weights

Weights of the rats were recorded at Day 0, 7, 14, and 21. The fourth set of mammary fat pads and
additional single fat pad from 5th set of mammary fat pads were dissected from rats and weighed.

3.4.2.2

High Frequency Ultrasound

High frequency ultrasound images were analyzed using Vevo2100 ultrasound Imaging System.
Each rat underwent ultrasound at Days 0, 14, and 21. As mentioned, only two of five rats in each
group were analyzed on Day 7.
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3.4.2.2.1 Thickness
For each fat pad, the midline was marked as the center of the nipple. Measurements of the fat pad,
as well as the fat pad with the skin were taken at 2 mm proximal and 2 mm distal to the marked
midline in Vevo2100 software. 2 mm was chosen because it was the closest measurement that was
consistently possible to the nipple yet still avoid the mammary fat pad distortion associated with
the ducts feeding the nipple at midline.

3.4.2.2.2 Volume: 3D Reconstruction
The same midline measurement was used as that used for thickness measurements in Vevo2100
software. The fat pad was contoured using the lasso tool at midline, at 5 mm proximal and at 5
mm distal to the mammary fat pad. These measurements were taken as the fat pads were
consistently captured within these parameters – often further than that, the fat pad would “drop
off” if the rat was smaller in size. The software was programmed to fill in the rest of the fat pad
between these contour levels. The contours were checked by scrolling through the images (step
size of each image is 0.083 mm) and adjusted as needed to reflect the mammary fat pads as accurate
as possible.
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4

Results

Our preliminary experiments radiation experiments from section 3.2.1 demonstrated hardening of
the fat pad as noted by digital palpation as early as two weeks. Further hardening was noticed on
palpation at 3 weeks, and animals were euthanized at that point. Masson’s trichrome (SigmaAldrich) staining revealed higher collagen fibril density in mammary fat pads from contralateral,
non-irradiated glands of radiated animals compared to mammary fat pads isolated from nonirradiated control animals, suggestive of a systemic inflammatory response. The clinical findings
provide a suitable model to test our hypothesis further.

Following these initial studies of low and high dose radiation in rats, a high dose of 26 Gy was
deemed appropriate for subsequent radiation studies. Ten of twenty retired female breeder rats
were irradiated with 26 Gy at the fourth mammary fat pad. Radiation changes were evaluated
through clinical skin assessments and biomarker analysis via immunohistochemistry and
quantitative PCR.
The irradiated rat mammary fat pads exhibited significantly higher scores on the Kumar Scale, a
skin assessment scale previously used measure of cutaneous radiation injury for animals
(Supplemental Figure 2)37, amongst all days when compared to non-irradiated rats when evaluated
by a clinical expert in radiation-skin changes in a blinded fashion (***p=.005; Figure 5A). When
specific days were analyzed, the radiation oncologist expert observed differences in the two groups
at Day 7 and 21 (equal variances not assumed; *p=.0125 and **p=.0045 respectively; Figure 5B).
The clinical expert also found a difference amongst all days (**p=.0015; Figure 5C) using the
Radiation Therapy Oncology Group (RTOG) toxicity scoring system. In particular, when we
compared the two groups using the RTOG on day 7 alone, we found a significant difference
(*p=.022; Figure 5D). These results show that the applied dose of radiation resulted in acute and
clinically visible changes in the exposed skin (Supplemental Figure 5). To determine if this dose
also resulted in chronic skin fibrosis typical of radiofibrosis observed in human skin, pro-fibrotic
markers were measured.
An increased density of collagen fibrils is typical marker for radiofibrosis. This property was
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measured by Picrosirius red staining of histology sections from tissues from day 21 that were
imaged with polarized microscopy. As shown in Figure 6, radiation induced a strong increase in
collagen fibril density. (*p =.025). A similar, though non-significant result was observed when
collagen was detected using Masson’s trichrome staining as well (Supplemental Figure 6). There
was a tendency (p=.07) towards increased expression of active TGFb1 in immunohistochemical
studies of mammary fat pad sections. TGFb1 is typically expressed within the first week of
damage, and so it is not unexpected that a significant change was not observed in this series of
experiments (Figure 6).
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Supplemental Figure 6. Masson’s Trichrome staining of representative images from one rat
(left and right fat pads)
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Figure 5. Radiation group had significantly greater clinically detectable skin changes than
non-irradiated control group with the Kumar scale and RTOG skin scoring systems. Skin
assessments were performed by a radiation oncologist on control and irradiated rats in all days,
using the Kumar and RTOG scoring systems A. Clinical Expert Evaluation mean score across all
days with Kumar scale (***p=.0005) B. Clinical Expert Evaluation with Kumar Scale, days
separated (**p=.0045; *p=.0125) C. Clinical Expert Evaluation mean score across all days with
RTOG scale (**p=.0015) D. Clinical Expert Evaluation with RTOG scale, days separated
(*p=.022) Values are the Mean, analysis with 1-tailed t-tests. n = 5 rats.
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Figure 6. Markers of fibrosis are increased in irradiated groups compared to
non-irradiated control in immunohistochemical studies. Paraffinized sections
in control and irradiated rats euthanized at Day 21 were stained for markers of
fibrosis A. Representative images stained with H&E B. Representative images
stained with Picrosirius Red, red indicating denser collagen bundling and networks,
at 40x C. Representative images stained with Masson’s Trichrome D.
Representative images stained with TGFβ1, brown is positive staining for TGFβ1,
at 5x E. The percentage staining per an area that expressed red when stained for
Picrosirius Red (*p=.025) F. The percentage staining per an area of fat pad at day
21 for TGFβ1 (p=.07). Values are the Mean, analysis with 1-tailed t-tests. n = 5
rats, 5 images/fat pad, two fat pads/rat.
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To further probe pro-fibrotic changes in the radiated rodent skin, qPCR analyses of TGFb1,
Collagen-1, and Collagen-3 mRNA were performed. An increase in the Collagen-1 to Collagen-3
ratio is typical of scarred fibrotic tissue. Adipogenic markers were also evaluated since radiation
has been observed to inhibit adipogenesis. Markers included the “master” adipogenic transcription
factor, PPARg and one of its targets the adipokine adiponectin, However, significant changes in
mRNA expression was not observed in the control vs. radiated groups (Figure 7).

A goal of this study was to reduce tissue fibrosis in order to create a more favorable
microenvironment to support autologous fat grafts. Thus, the effect of RHAMM mimetic peptides
– (NPI-110) which have previously been shown to inhibit fibrosis and promote adipogenesis55,63,78
in uninjured dorsal skin and mammary fat pads – on radiofibrosis in the mammary fat pads of the
irradiated rat model was next assessed. Visible skin changes were not appreciably different
between the radiated and peptide treated groups when the cumulative score was assessed using the
Kumar and RTOG scales (Supplemental Figures 7-9).
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Figure 7. No difference in fibrotic markers were found in qPCR studies. Real time
PCR was performed for markers of fibrosis in non-irradiated (control group) and irradiated
rat whole mammary fat pads A. TGFβ1 (*p=.045) B. Collagen-1:Collagen-3 (p=.118) C.
PPARg (p=.085) D. Adiponectin (p=.063). Values are the Mean, analysis with 1-tailed ttests. n = 3 rats, 3 technical replicates/fat pad, two fat pads/rat.

47

Day 0

Day 7

Day 14
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Supplemental Figure 7. Representative Images of right fourth mammary fat pad rats in
control and radiation group at Days 0, 7, 14, and 21.
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Supplemental Figure 8. Images of right fourth mammary fat pad rats in radiation and
radiation + peptide group at Day 0, 7, 14, 21 (Rat 4 and 5 of each group respectively).
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Supplemental Figure 9. Peptide (NPI-110) did not reduce severity of clinically appreciable
skin changes in irradiated rats. Skin assessments were performed by an expert clinician treated
and non-peptide treated groups amongst irradiated rats using the Kumar Scale and RTOG scale A.
Clinical Expert Evaluation mean score across all days using Kumar scale (p=.15) B. Clinical
Expert Evaluation mean score across all days using RTOG scale (p=.057) C. Clinical Expert
Evaluation using Kumar Score, days separated D. Clinical Expert Evaluation using RTOG score,
days separated. Values are the Mean, analysis with 1-tailed t-tests. n = 5 rats.

50

While there was no difference in visual appearance, peptide-treated irradiated skin strongly
reduced collagen fibril formation as detected by Picrosirius red staining (**p=.003). Masson’s
trichrome staining qualitatively showed a similar effect. Active TGFb1 trended to a lower level in
the peptide group (p=.075). These results show that the RHAMM mimetic peptides strongly
reduces radiofibrosis as detected by collagen fibril formation (Figure 8). There was no difference
found between radiation and peptide treated group as compared to the control group when
Picrosirius Red staining was examined; the peptide treated radiation group was found to decrease
expression of active TGFb1 as compared to the control group (Supplemental Figure 10). We used
mammary fat pad tissues to quantify the amount of TGFb1, ratio of Collagen-1 and Collagen-3
via quantitative PCR in the irradiated rats. We found no difference in the expression of these
markers amongst the two groups, however (Supplemental Figure 11).

In order to assess if these changes in tissue fibrosis are accompanied by altered adipogenesis,
adipokine expression was analysed by qPCR. These included adiponectin (ADIPOQ), and
PPARg55. We also analyzed the mammary fat pad for volume and thickness changes using high
frequency ultrasound, but these were not significant (Supplemental Figure 12, 13).

qPCR analyses showed a significant increase in the adipokine adiponectin (Figure 5) (*p=.014) at
Day 21 (when rats were euthanized). There was a trend towards increased expression of PPARg in
the peptide treated group (p=.055) and a tendency towards an increase of PPARg expression
(Figure 9). These results suggest that the RHAMM function blocking peptide promotes a proadipogenic microenvironment.

We also used paraffin processed mammary fat pad specimens to quantify the amount of staining
for immunohistochemistry markers of adiponectin. We found that there was no trend towards
expression of adiponectin in the peptide-treated group as compared to the non-peptide treated
group amongst irradiated rat (Supplemental Figure 14) on day 21.
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Figure 8. Markers of fibrosis are decreased in peptide-treated groups compared to
non-peptide treated groups amongst irradiated rats in immunohistochemical studies.
Paraffinized sections in peptide and non-peptide treated groups euthanized at Day 21 were
stained for markers of fibrosis A. Representative samples stained with H&E B.
Representative samples stained with Picrosirius Red, red indicating denser collagen
bundling and networks, at 40x C. Representative samples stained with Masson’s Trichrome
D. Representative samples stained with TGFβ1, brown is positive staining for TGFβ1, at
5x E. The percentage staining per an area that expressed red when stained for Picrosirius
Red (*p=.003) F. The percentage staining per an area of fat pad at day 21 for TGFβ
(p=.078). Values are the Mean, analysis with 1-tailed t-test. n = 5 rats, 5 images/fat pad,
two fat pads/rat.
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Supplemental Figure 10. Markers of fibrosis in peptide-treated groups compared to control
in immunohistochemical studies. Paraffinized sections in peptide and non-peptide treated groups
euthanized at Day 21 were stained for markers of fibrosis A. The percentage staining per an area
that expressed red when stained for Picrosirius Red (p=.109) F. The percentage staining per an
area of fat pad at day 21 for TGFβ (*p=.025). Values are the Mean, analysis with 1-tailed t-test. n
= 5 rats, 5 images/fat pad, two fat pads/rat.
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Supplemental Figure 11. Peptide NPI-110 did not affect markers of fibrosis in qPCR studies.
Real time PCR was performed for markers of fibrosis in peptide and non-peptide treated groups in
irradiated rats A. TGFβ1 (p=.074) B. Collagen-1:Collagen-3 (*p=.032). Values are the Mean,
analysis with 1-tailed t-test. n = 3 rats, 3 technical replicates/fat pad, two fat pads/rat.
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Supplemental Figure 12. Peptide NPI-110 did not affect volume of fat pad amongst
irradiated rat in ultrasound measurements. 3D volume reconstruction was performed on fat
pads on live rats in Day 0, 14, and 21. A. Between Day 0 and Day 14 (p=.64) B. Between Day 7
and Day 14 (p=.33). Values are the mean percentage difference of fat pad volume compared to
Day 0, analysis with 1-tailed t-test. n = 5 rats/group, two fat pads/rat.
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Supplemental Figure 13. Peptide NPI-110 did not affect thickness measurements of the
mammary fat pad between the peptide and non-peptide treated group amongst irradiated
rats in ultrasound measurements. Thickness measurements (mm) was performed on fat pads on
live rats in Day 0, 7, and 21 under high frequency ultrasound A. Mammary fat pad thickness
percentage differences between day 0 and 7 (p=.12) B. Mammary fat pad thickness percentage
differences between day 0 and 21 (p=.45) Values are the mean percentage difference of thicknesses
compared to Day 0, analysis with 1-tailed t-test. n = 5 rats/group, two fat pads/rat.
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Supplemental Figure 14. Peptide NPI-110 did not increase expression of adipogenic marker
adiponectin in immunohistochemical study amongst irradiated rats. Paraffinized sections in
peptide and non-peptide treated groups amongst irradiated rats euthanized at Day 21 were stained
for adipogenic marker, adiponectin A. Representative sections of mammary fat pad stained with
adiponectin; brown is positive staining for adiponectin B. qPCR results Adiponectin (p=.093).
Values are the Mean, analysis with 1-tailed t-test. n = 5 rats, 5 images/fat pad, two fat pads/rat.
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5

Discussion

The central hypothesis of this study is that the injection of RHAMM mimetic (NPI-110) peptides
decrease fibrosis and increase adipogenesis in a rat model of radiation induced mammary fat pad
fibrosis. We demonstrated that radiated rats scored significantly higher on clinical skin assessment
scales, a measure of cutaneous radiation injury for animals. Pro-fibrotic markers such as active
TGFβ1 and collagen density were increased in the irradiated mammary fat pads when analyzed
through immunohistochemical means. RHAMM mimetic peptide NPI-110 strongly reduced active
TGFβ1 and collagen fibril formation amongst irradiated rats through immunohistochemical
analyses. RHAMM mimetic peptides NPI-110 also increased expression of adiponectin, an
adipokine in qPCR analyses amongst irradiated rats.

Objective 1: Create a rodent model of radiation-induced mammary fat pad fibrosis
We describe in this study radiation-induced inflammatory (dermatitis) and fibrotic changes in
mammary fat pads. There are other studies that have, using different radiation doses, observed
radiodermatitis, radiation-induced lesions, and radiofibrosis in the skin of animal models. De
Andrade et al. used 10 Gy, 40 Gy, and 60 Gy on dorsal excisional wounds in rats that resulted in
macroscopic and microscopic injuries to rat skin with increasing doses of radiation. In wounds,
visible skin changes, increased collagen fibril formation, and increased TGFβ1 expression were
observed as early as five days after injury even at lower doses104. Chronic changes in response to
ionizing radiation have also been studied in other animal models. For example, in leg contracture
models, mice exhibit progressive leg contracture and fibrosis when administered single doses of
radiation between 20-80 Gy105. However, to our knowledge, our study is the first report of radiation
induced mammary fat pad fibrosis. From our preliminary experiments, the 26 Gy model was
chosen because it demonstrated clinically palpable and observable changes. However, the 13 Gy
model may also have been chosen, as more occult, lower doses of radiation changes are still
associated with long term clinical sequelae8,24,30.
Radiation fibrosis is a dynamic process, characterized by constant remodeling and long-term
fibroblast activation. In normal wound repair, fibroblasts are transiently activated into
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myofibroblasts to facilitate wound remodeling. Terminally differentiated myofibroblasts undergo
apoptosis and normal tissue architecture is mostly restored. However, in fibrotic tissue, chronic
myofibroblast activation is observed, which is thought to result from elevated levels of growth
factors including TGFβ1, PDGFb, TNFa, bFGF’s, GM-CSF, IL-1, IL-4, CTGF106,107. In animal
models of lipodystrophy and scleroderma, these pro-fibrotic cytokines reduce the survival of
adipocyte progenitor cells57,106,108. Adipogenesis is also restrained by the rigid microenvironment
produced by myofibroblasts’ ability to promote collagen fibrillogenesis57. Loss of adipocytes also
contributes to progressive tissue fibrosis since many adipokines are anti-fibrotic. This is
particularly true of adiponectin56. Our results support this connection between adipocytes and
fibrosis since the RHAMM mimetic peptides reduced fibrosis concomitantly with an increase in
adiponectin expression (Figure 9).

Other tools may be considered to measure clinically observable skin and fibrotic changes. One
includes image processing programs that can measure amount of redness in skin as a proxy for
erythematous changes. Optical coherence tomography (OCT) is a non-invasive imaging modality
that provides an in vivo cross-sectional image of tissues through the use of low-coherence
inferferometry, and is used in clinical diagnosis in dermatology and other fields in medicine. It has
the capacity to image skin collagen through its orientation, organization and reflective properties,
and uses light instead of sound (as in ultrasound) to generate images109. Skin elasticity as a measure
of radiation fibrosis through newer methods has been reported with the DermaLab suction cup
system; it shows promise in generating reproducible measurements of radiation-induced skin
fibrosis110.

Objective 2: Examine the effect of RHAMM mimetic peptides on fibrosis in irradiated
mammary fat pads

We did not observe an increase in either the expression or activation of TGFβ1 or an altered
Collagen-1 to Collagen-3 ratio that has been reported for other animal models of radiation. TGFβ1
has been detected in skin as early as 6 hours after g-radiation111. Increased levels of TGFβ1 were
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also found at 6 hours post-irradiation in other studies, which returned to basal level within 48 hours
and increased after 14 days. In mouse mammary glands, one team has found that whole body
irradiation induced immunoreactivity at 1 hour, and persisted for 7 days. In addition, they found
that irradiation specifically generates the active (versus latent) TGFβ1, suggesting that low and
moderate doses of radiation induced the activation of latent TGFβ1 in the mouse mammary
gland112,113. Martin et al. describes two types of fibrosis: an immature, active, and inflammatory
fibrotic tissue examined in most studies, versus a non-inflammatory and poorly cellularized
fibrotic tissue that correspond to studies of samples 10-20 years after irradiation33. Of note, the
young fibrosis samples contained a high proliferation rate of myofibroblasts, and a high secretion
of TGFβ1, whereas the older type of fibroblasts exhibited reduced proliferation and low secretion
of TGFβ1114,115.
Through previous immunohistochemical studies, collagen-1 at one day after irradiation appeared
to be reduced in the stromal sheath, while collagen-3 appeared reduced in the periepithelial stromal
sheath but stronger along septa. Increased abundance of collagen-3 staining was noted in both the
periepithelial stroma and stroma at day 3; this new collagen-3 expression in the adipose stroma colocalized with that of new TGFβ1 expression113.
To date, there is no approved clinical treatment for radiofibrosis, and few current options are
available for restricting or reversing tissue fibrosis resulting from other forms of tissue injury.
Although TGFβ1 is considered a master switch for promoting myofibroblast differentiation and
survival and for reducing anti-fibrotic adipokine production, this cytokine has not been useful for
clinical control of fibrosis likely because of its ubiquitous expression and multifunctional nature.
Another potential target that has emerged is PPARg, which regulates both inflammatory and
fibrosis processes. In particular, the PPARg agonist rosiglitazone has been reported to protect mice
against radiation induced inflammation and reduced expression of both TGFβ1 and Collagen-1116.
Unfortunately, the use of rosiglitazone is currently restricted in humans due to trials showing
increased drug related cardiovascular toxicity. One of the PPARg target genes, adiponectin, may
be a more promising approach for reducing some forms of tissue fibrosis and clinical trials are
currently ongoing for non-alcoholic fatty liver disease117. Thus far, in animal models, adiponectin
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does not appear to play a role in radiation induced intestinal damage in mice118 and its anti-fibrotic
effects may be restricted to specific tissue and stimuli.

We propose that blocking RHAMM function using mimetic peptides is an efficacious alternative
approach to controlling tissue fibrosis resulting from radiation as it did from other forms of tissue
damage101. RHAMM mimetic peptides are predicted to be particularly useful for reducing
radiofibrosis in breast tissue since they create a microenvironment that supports adipogenesis. This
is predicted to both contribute to a reduction in fibrosis (e.g. through elevated production of
adiponectin) and to provide a method for supporting the survival and differentiation of adipocytes
in autologous fat grafts. To date, RHAMM mimetic peptides have a good safety profile in animal
models likely due to the restricted expression of this protein in homeostatic tissues. RHAMM
expression is an integral part of the response of tissues to stress and to disease. Its primary functions
appear to be control cellular migration and mesenchymal differentiation during repair processes119–
122

.

Objective 3: Examine the effect of RHAMM mimetic peptides on adipogenesis in irradiated
mammary fat pads

Previous studies showed that the injection of RHAMM mimetic peptides result in a detectable
increase in mammary fat pad size as measured by microcomputer tomography (MicroCT)55. High
frequency ultrasound is a more common imaging modality that has recently evolved as a result of
more sophisticated technology and computer programs123,124. High frequency transducers (>15
MHz) have been used to successfully study the vascularization of expansion of lesions in the skin
lesions, skin diseases such as psoriasis, scleroderma, erythema nodosum, among others123. More
recently, Santolo et al. has evaluated the use of doppler ultrasound examination (ECD) in
autologous adipose tissue filling by a plastic surgeon in the setting of post-surgical, post-traumatic,
and post-burn scars in patients124. They obtained quantitative data with ultrasound examination
representing various skin and subcutaneous layers in serial evaluations after lipofilling procedures,
and thus a subsequent average percentage of one-year survival of autologous implanted fat was
possible. Other authors have used ultrasound as a non-invasive, quick, and low-cost technique to
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study fat necrosis, and subcutaneous tissue for pre-operative planning and document postoperative results in the context of lipofilling125–127. Our study, however, was not able to detect any
changes in fat volume with high frequency ultrasound. This will be elaborated upon below.

Our lab has previously injected adipogenic RHAMM mimetic peptides into dorsal rat skin and
mammary fat pads, and has found increased dorsal back subcutaneous fat pad area and mammary
fat pad size using micro CT imaging. Peptide-induced fat pad surface area in dorsal skin tissues
was significantly larger than vehicle controls at day 21, and maintained until Day 35 with respect
to fat pad retention when examined via micro-CT. Over-expression of RHAMM downregulates
adipogenic transcription factors PPARg, adiponectin, and perilipin via qPCR analysis. Our lab has
shown that these RHAMM mimetic peptides upregulate expression of PPARg and adiponectin55.
Consistent with this, we demonstrated an increased expression of adiponectin and a trend towards
increased PPARg expression in our study. Although we did not demonstrate tissue architecture
change, we provided molecular evidence for a marker change with our qPCR studies. PPARg
directly regulates adiponectin expression, and is made by subcutaneous fat; it is therefore the best
marker for adipogenesis that we currently have. Oil Red O uptake into fat droplets is another
method used to measure adipogenesis that our lab used previously, which may be another valuable
adjunct in measuring NPI-110’s effects55.

5.1

Stem Cells and Fat Grafting

Adipose-derived stem cells from the stromal vascular fraction of fat harvest is thought to play a
large role in fat take. It can be harvested with minimal morbidity, differentiated reliably down
various pathways, and can be transplanted in a safe fashion with modern liposuction techniques128.
Growth hormone, insulin, glucocorticoids, and prostaglandins stimulate ASCs in adipocyte
differentiation in its initial and final stages. As such, adipogenic media are often supplemented
with dexamethasone, human recombinant insulin, indomethacin, and second messenger cyclic
adenosine monophosphate (cAMP) inducer 3-isobutyl-1-methyl-xantine (IBMX), to activate gene
expression involved in adipogenic differentiation129. These conditions will lead ASCs to acquire
intracellular lipid droplets and morphology specific to lipid-laden cells, and adipocyte marker
expression of adiponectin and PPARg129. Early stage adipogenic genes have been identified and
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include Krox20, KLF5, C/EBPβ, C/EBP∂. Late stage adipogenesis regulators include KLF15,
C/EBPα, PPARg, and aP2130. Adipocyte stem cell markers include CD34 and Sca-1, and preadipocyte markers include Gata2 and Pref-1130. Future studies would look at the effect of our
peptide on adipocyte differentiation, in looking at these factors within our tissue samples via
immunohistochemistry and qPCR.
The ultimate goal would be to create a micro-environment, with adipogenic media and potential
supplementation of RHAMM mimetic peptides (or RHAMM function blocking peptides) that
would facilitate greater fat take and adipogenesis. It is widely understood that volume retention of
the graft, or “fat take” is variable. Studies have suggested that successful grafting, or “good fat
take” has been linked to the presence of progenitor cells and their ability to undergo adipogenesis11.
There are numerous techniques for fat harvest and fat processing. The lipoaspirate from fat grafting
contains pre-adipocytes and mature adipocytes, with the pre-adipocyte (10% of cell population)
responsible for graft survival due to their large capacity for proliferation131. Recent literature in
this area emphasizes the importance of this adult stem cell population or fraction in fat grafting. It
is thought that these adipose derived stem cells (ASCs), which are of mesenchymal stem cell
(MSC) origin, have the capacity to differentiate into specialized cell types to have reparative
effects in their home tissue132, and promote long-term volume stability, survival, and outcome
predictability133,134. Lipoaspirates have shown great potential to create viable natural tissue in
addition to damaged tissue10,135,136. A study has recently shown that adipose-derived stem cells from
lipoaspirates led to clinical improvement in the late side effects of radiotherapy (healing of ulcers,
remission of fibrosis, atrophy, and retraction10. There is thus interest in stem cell therapies, or stem
cell enhanced fat grafting to promote greater volume retention of graft. In mice, adipose stromal
stem cells have been shown to secrete angiogenic and antiapoptotic factors, and promote
neovascularization in ischemic tissues by differentiating into endothelial cells and incorporating
into blood vessels137,138.
Autologous fat transplant, also known as fat grafting, is a common technique for breast revision
surgery139. It has emerged as a promising technique with a relatively low complication rate that
improves contour, shape, and volume following breast reconstruction. Furthermore, experimental
models and clinical research have shown that successful autologous fat grafting reduces fibrosis
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from various stimuli, including radiation139.
Fat grafting in post-mastectomy radiation patients undergoing two-stage breast reconstruction with
a traditional tissue expander has shown promise in better reconstructive outcomes with the creation
of new subcutaneous tissue, improved skin quality, and reduced capsular contracture rates140. There
is evidence to suggest that fat grafting may reduce morbidity associated with radiation-induced
fibrosis including post-mastectomy pain, scarring, and arm movement restriction as well10. The
ability of fat grafting to reverse some of the late changes associated with radiation is promising in
the clinical context; it is a clinical target for breast cancer reconstruction patients in its ability to
reverse radiation-induced soft tissue damage and dermal fibrosis.
From an oncological perspective, there has traditionally been concern with the safety of fat grafting
at the breast level. Most of this concerned the potential for necrosis and micro-calcification of
breast tissue that would be misleading on radiographic mammography11. In addition, the
interaction of grafted adipose tissue with host cancer cells, as well as the long-term effects of fat
and cell transplantation in a microenvironment of highly reproductive tissue or residual tumour
cells are unknown11,141–143. Recommendations thus exist for patient selection for autologous fat
grafting to the breast: risk factors such as BRCA-1, BRCA-2, positive personal or family history
of breast cancer would warrant mammography prior to surgery11,144. Fat grafts enriched with
processed adipose derived stem cells have been used in breast reconstruction following
mastectomy and in non-oncologic breast augmentation without adverse outcome; however, no
long term data is present145,146. More research in long-term clinical studies in this area is needed,
and it is suggested that until then, conventional fat grafting is safe in certain subgroups of patients,
whereas an increase in stem cell fraction through various means cannot be recommended at
present11.

5.2 Limitations and Future Directions
One limitation of the current study is technical. A rat model was chosen as a model due to previous
mammary fat pad and radiation studies. As compared to the mouse or guinea pig, the rat is larger
in size and thus easier to study the mammary fat pad. Due to economic and practical administrative
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reasons of a pilot study, a model that more closely resembles human skin were not selected. Our
rats were retired breeders between the ages of 6-12 months, but their exact dates of birth are
unknown.
Although ultrasound has been used to study lipofilling and adipose tissue in the previous studies,
to our knowledge, our study was the first attempt to use high frequency ultrasound to quantify the
volume of a rodent mammary fat pad. Attempts were made to set up rats in the same position for
every measurement, but even so, slight movement of the rat or centering the probe on the nipple
may not be identical each time and could affect the measurement. Slight angulation and rotation
may have affected the field of capture as well. Efforts to bypass this were made by measuring
thickness of mammary fat pad in addition to contouring the volume, whereby the irregularities
around the nipple wouldn’t confound the accuracy of measurement. Other potential confounders
include variation in ultrasound gel and pressure of the, potentially affecting the consistency in
measurement of the fat pad secondary to differences in compression. Lastly, as with human breast
volume, there exist natural variations in rat volume, and so perhaps we were unable to detect
significant differences due to this with our sample size. Percentage change within rat weights,
volume, and thicknesses were used to control for this, but again we saw no differences between
the studied groups. We would recommend future studies repeat with a greater sample size, and
have it compared to other methods of volume assessment. We believe that measuring fat volumes
would thus be difficult unless there are very large increases in adipocyte differentiation, and that
these imaging techniques are not robust or sensitive enough to detect small changes. Molecular
markers such as PPARγ and adiponectin would thus be worthwhile adjunctive measures.

Although there were five rats per group studied, three rats per group were allocated to qPCR
studies, and two rats remaining per group allocated to immunohistochemistry. This was done to
preserve the homogeneity of the tissues – as the radiation probe was 1 cm in diameter, it was not
possible to separate or identify the purely irradiated portion of the fat pad. Only dissecting the
whole fat pad would provide a tissue sample representative of the rat, and trying to split the fat
pads in half would not capture necessarily the irradiated part of the tissue. In addition, more
replicates or drop PCR may be more appropriate; three technical replicates were done in this case
and were likely not sufficient.
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Furthermore, quantification in immunohistochemistry relies on calculating pigment density as an
indicator of presence of marker of interest. There is inherent variability and uptake in the
penetration of the stain, even though steps were taken to minimize the variability – ie, staining all
sections in the same conditions as best as possible. Quantification methods do not capture the
whole section, but rather, snapshots within the section. Although performed in a randomized
fashion, it is possible that some staining was over-estimated or under-estimated because of this
sampling bias; as mentioned above it is unknown where exactly on the fat pad that the irradiation
beam focused on. This may affect the results as we are essentially piloting this method, and may
suffer from low sensitivity.
Future studies would look at sacrificing animals within the one-week mark as TGFβ1 is an early
inflammatory marker, and after 6 months as perhaps a more accurate representation of chronic
radiation fibrosis. The studies above support using TGFβ1, Collagen-1 and Collagen-3 as markers
of fibrosis. Additional future work with these mimetic peptides will be directed towards assessing
their ability to promote pre-adipocyte survival and differentiation in fibrotic microenvironments.

Future studies of interest would involve repeated injections of peptide, as its effect have been
shown to be at its peak at 14 days in our previous studies55; our animals in this case would be
observed for as long as 6 months.

Our goal is to create a micro-environment, with adipogenic media and potential supplementation
of RHAMM mimetic peptides, that would facilitate greater fat take and adipogenesis with fat
grafting. Our model had demonstrated clinically appreciable skin changes after radiation. Previous
studies have described fat grafting or transplant to have an effect on skin quality. We would thus
like to further assess the effects of the NPI-110 at these multiple injection times, on its own and in
conjunction with fat grafting.
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6

Conclusion

Radiation damaged skin as a result of radiotherapy is characterized by both acute and chronic
changes, and can be replicated in an animal model. Here, a model for radiation-induced mammary
fat pad has been developed, with an increase in observational skin changes, and increased collagen
bundling and expression of fibrotic marker TGFβ1. RHAMM mimetic peptides (NPI-110) have
been shown to promote adipogenesis and decrease fibrosis in previous animal models. Here, we
show that NPI-110 increase expression of an adipogenic marker and decrease fibrotic markers in
such a rat model of radiation-induced mammary fat pad fibrosis. These results support the further
investigation of this approach to ultimately reduce radiofibrosis and improve breast reconstruction
in breast cancer patients.
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Abstract
Radiofibrosis of the breast makes satisfactory breast tissue reconstruction challenging and is
associated with a high risk of complications. Autologous fat grafting can improve surgical outcome
but fat retention is often variable. We developed RHAMM mimetic peptides (NPI-110) that
decrease chemotherapy induced fibrosis and increase subcutaneous adipogenesis by promoting the
differentiation of mesenchymal progenitor cells. Here, we assessed the efficacy of these peptides
in reducing radiofibrosis of rodent mammary fat pads. A model of radiation-induced mammary fat
pad fibrosis was developed in retired breeder rats that exhibits acute skin inflammation and a robust
increase in collagen fibril deposition. This model was used to quantify both the effect of the NPI110 on radiofibrosis and the promotion of a microenvironment that supports adipogenesis. Acute
skin changes were scored from photographs, fat pad volume estimates were quantified using high
frequency ultrasound, mRNA expression of genes involved in fibrosis (Collagen-1, Collagen-3,
TGFß1) and adipogenesis (PPARγ, adiponectin and perilipin) using QPCR, and collagen fibril
deposition using polarized microscopy of picrosirius red stained paraffin processed mammary fat
pad tissue sections. NPI-110 significantly reduced radiation-induced skin inflammation,
radiofibrosis as assessed by reduced collagen fibril deposition and increased mRNA expression of
adipogenesis markers adiponectin and PPARγ Results from this study will aid in creating a microenvironment that optimizes autologous fat transplantation success.
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1. Introduction
1 in 9 Canadian women will develop breast cancer in her lifetime, and 1 in 30 will die from it.
Approximately 45-50% breast cancer patients undergo curative radiotherapy2–4. Recent data has
shown that post-mastectomy radiation therapy reduced the rate of locoregional recurrence in nodepositive patients from 27% to 9%5.
The use of ionizing radiation is predicated on attempting to achieve lethal effects on tumour cells
while sparing normal tissue12. Newer technologies such as conformal radiation techniques and
intensity-modulated radiation therapy (IMRT) have considerably reduced the area of skin toxicity7
but the higher beam intensities have increased the localized risk of fat pad fibrosis 2. Although not
life threatening, fibrotic breast tissue is challenging to reconstruct and contribute to variability of
autologous fat grafting success in these patients.
Radiation injury may be categorized as acute or chronic (late), with acute injury occurring within
hours to weeks after radiation exposure, and chronic injury presenting months to years after
radiation exposure7–9. Acute injury primarily involves skin cell death through cellular alterations
and inflammation in the epidermis and begin with erythema, edema, pigment changes, and deepilation8. Severe acute injury involves complete loss of epidermis, persistent edema, fibrinous
exudates and disturbance in skin barrier function8,13. Later, chronic effects include but are not
limited to chronic inflammation, delayed ulcers, telangiectasias, atrophy, and fibrosis2,8.
Chemotherapeutic drugs have been discovered to induce radiosensitivity which is more effective
in killing tumor cells but a side effect is often more xerosis, inflammation, thinning, and necrosis
of surrounding normal skin. This condition can develop into a dynamically progressing fibrosis
with reversible and irreversible components in approximately 35% of patients18,19. The underlying
mechanisms driving the development of such radiation-associated damage are not well understood,
due in part to a lack of suitable pre-clinical models 8. As a result of this knowledge deficit, there is
currently no effective intervention, by topical or systemic means, to prevent or favorably modify
the course and severity of dermatitis3,7–9.
TGFβ1 is a peptide and cytokine that has many functions that include promoting development of
chronic inflammation, radiation dermatitis and fibrosis 33. TGFβ1 activates fibroblasts to secrete
extracellular matrix proteins including collagens24,34–36 147. Up-regulation of TGFβ1 is common in
the fibrotic tissues of irradiated patients and induction of its expression is a major cellular response
to ionizing radiation34. Additionally, TGFβ1 and other pro-inflammatory, pro-fibrotic cytokines
such as interferon, IL-1, IL-2, and tumour necrosis factor a (TNFa) inhibit adipogenesis.
Collectively, the sustained presence of these cytokines create a microenvironment that is hostile
to the survival of mesenchymal stem cells, which compromises the success of tissue
reconstruction. Fibrosis in response to growth factors such as TGFβ1 may be focal or widespread
and also contribute to tissue retraction, restriction of movement, and chronic pain that can be
difficult to manage34. The development of effective radiation mitigators and protectors, and the
elucidation of the mechanisms responsible for radiation-associated changes in skin and other
normal tissues are therefore a necessary part of breast cancer patient management 21.
A prior history of radiation treatment affects the complication profile and available breast
reconstructive alternatives. There is an increasing number of patients receiving post-mastectomy
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radiation therapy, and the timing and technique of breast reconstruction in this population is
controversial43. Alloplastic, or tissue expander and implant based reconstruction, is the most
common method for breast reconstruction after radiotherapy. Studies evaluating such two-stage
breast reconstruction in post-mastectomy radiation therapy patients with implant following tissue
expander placement reveal consistently high rates of acute and chronic complications such as
capsular contractures and poor aesthetic outcomes44. Ascherman et al. found higher complication
rates, extrusion rates, and asymmetry for irradiated breasts as compared to non-irradiated breasts
in patients who underwent two-stage implant-based reconstruction45.
Fat grafting has emerged as a promising technique with a relatively low complication rate that
improves contour, shape, and volume following breast reconstruction. Furthermore, experimental
models and clinical research have shown that successful autologous fat grafting reduces fibrosis
from various stimuli, including radiation49. There is evidence to suggest that fat grafting may
reduce morbidity associated with radiation-induced fibrosis including post-mastectomy pain,
scarring, and arm movement restriction10. These optimal properties of fat grafting result in part
from the ability of mature adipocytes to reduce tissue rigidity by altering the mechanical properties
of connective tissue, thus blocking the differentiation and survival of myofibroblasts and from
anti-fibrotic functions of adipokines such as adiponectin and leptin. Therefore, development of
therapies that can enhance the long-term survival of adipocyte progenitor cells would greatly
benefit successful reconstruction of breast tissue in cancer patients. One microenvironmental
factor that affects pre-adipocyte survival and differentiation is the tissue polysaccharide,
hyaluronan62.
Hyaluronan (or hyaluronic acid, HA) is a carbohydrate in the glycosaminoglycan family in
mammalian tissues66. It is a major extracellular matrix (ECM) component, particularly in skin and
consists of repeating polymeric disaccharides D-glucuronic acid and N-acetyl-D-glucosamine
linked by alternating glucurinidic ß(1,3) and ß(1,4) bonds29,67,68. In its native high molecular weight
form, it plays an important role in tissue repair, has antioxidant properties and is a key component
of mesenchymal stem cell niches. When it is degraded into small fragments, which occurs in
response to stimuli such as ionizing radiation, it promotes inflammation and fibrosis69,70.
HA fragments mediate their pro-inflammatory and pro-fibrotic effects through interactions with
specific cell-surface receptors. The receptor of hyaluronan mediated motility (RHAMM) is one
such cell surface receptor that is only expressed during tissue inflammation and repair. The binding
of extracellular hyaluronan to RHAMM, which couples with CD44, plays a key role in activating
signal cascades MAP kinases, ERK1,2 controlling the cell migration that is required for initiation
of inflammation and fibrosis74,93.
RHAMM mimetic peptides have recently been developed that block the binding of RHAMM to
HA fragments. These peptides fall into two categories that act either by directly binding to HA
fragment sizes that are typically generated in small amounts during tissue injury (Kd=10nM) or
by binding directly to RHAMM itself. One of these peptides, NPI-110 also promotes adipogenesis
by releasing the RHAMM-mediated block on PPARg expression. These peptides appear act
specifically on RHAMM regulated pathways since they do not affect these functions in RHAMM/- cells. The limited expression of RHAMM in homeostatic tissues predicts a good safety profile,
and since NPI-110 directly blocks fibrosis and promotes adipogenesis, we predicted it would be
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an efficacious therapy for reducing radiofibrosis and for creating a breast tissue microenvironment
more favorable to the survival of grafted fat.
In order to assess these potential effects of NPI-110, a rat model of radiation-induced mammary
fat pad fibrosis was developed. We show that NPI-110 significantly reduced radiofibrosis and
enhanced expression of adipokines. We propose that NPI-110 is therefore a potential adjunct to
fat grafting in breast reconstruction outcomes following radiotherapy.
2. Experimental
2.1 Peptide injection formulation. Patented (through World Discoveries, Lawson Health Research
Institute) function blocking RHAMM peptides 644KLKDENSQLKSEVSK (denoted NPI-110)
were synthesized and purified to >95% purity (ProSci and gift of Dr. L. Luyt, Western University
and Novare Pharmaceuticals Inc). Peptides dissolved in PBS (2mg/ml) were sterilized by filtration
through 0.22µm filter at a concentration of 2mg/ml and then mixed 1:1 with hyaluronic acid
(Orthovisc, Anika Therapeutics, Bedford, MA) for a final concentration of 1mg/ml. A vehicle
mixture of 1:1 of PBS (2mg/ml) and Orthovisc was formulated without the peptide mixed in for
the control group.
2.2 Animals Animal work performed at London Health Sciences Centre, London Regional Cancer
Program, and Robarts Research Institute conformed to animal use protocol 2009-060. Twenty
retired breeder female CD (Charles River) rats were used for experiments. Rats were known to be
at 6-12 months of age, caged in pairs in a temperature-controlled room with 12 hour light/dark
cycle, and fed a standard diet. The 4 treatment groups were the following: control (-/-), peptide
injection only (-/p), radiation only (r/-), radiation and peptide injection (r/p).
Radiation. Radiation was administered in radiation treated groups using a Therapax-150 (T-150)
unit to achieve a focused radiation beam of 2.37Gy/min (probe diameter: 1cm). Animals were
induced and maintained with isofluorane by nose cone during radiation. Hair over the 4th set of
nipples were trimmed with a razor in a 2cm diameter area. Rats were positioned supine in a rotated
fashion so that the fat pad and overlying skin were the main target of the radiation probe in a
manner similar to that mentioned above. Animals in the radiation group received a single dose of
26 Gy. Both mammary fat pads in the 4th set of nipples were irradiated in rats in the radiationtreated groups (n=10).
Peptide injection. Animals in the -/p and r/p groups received a single injection of 100µg peptide
in vehicle formulation (1µg/ml) as described above in the mammary fat pads of the 4th sets of
nipples. Animals in the non-peptide treated group received the same volume of injection of the
vehicle formulation without the peptide mixture (100µl). This was performed under direct
visualization under ultrasound on Day 0 as described below.
High Frequency Ultrasound. Ultrasound experiments were carried out at Robarts Research
Institute in the James Lacefield lab. Animals were induced and maintained by isofluorane by nose
cone during ultrasound. Rats were placed supine on a heated platform set to 35°C. A motorized
razor was used to remove hair over a 2 x 5 cm area overlying the 4th set of nipples on Day 0,
followed by Q-tip assisted application of Nair®. This was done to ensure clear images via
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ultrasound and only on the Day 0 to avoid further irritation of the skin. Subsequent ultrasound
images taken at Day 7, 14, and 21 were augmented by motorized razor trimming of hair regrowth,
and not by chemical de-epilation to reduce irritation to skin that may confound skin assessments.
A Vevo2100 ultrasound Imaging System (VisualSonics, Toronto, ON) equipped with a MS-550D
transducer was used for high frequency ultrasound data. The imaging resolution was 40 µm (axial)
and 80 µl (lateral); image acquisition was transmitted at 40 MHz, with an image width of 14.08mm,
and depth of 15mm. A thin layer of ultrasound gel (Aquasonic 100, Parker Laboratories, Fairfield,
NJ) was applied over the transducer and 2 x 5 cm area over the nipple of interest. The image
acquisition was set to B mode, a two-dimensional ultrasound image display composed of bright
dots, and centered on the nipple. This scanning process for 3D image acquisition utilized a step
size of 0.083mm, with a total distance of 44mm along the length of the rat centered on the nipple.
On Day 0, after the scanning was completed, the transducer was once again centered along the
nipple. A one-time 100ul vehicle formulation with (-/p and r/-) or without peptide (-/- and r/-),
depending on the treatment group was injected under the 4th nipple into the mammary fat pad.
Photographs were then taken at this time, while supine on the heated platform, with interest in the
skin condition over the 4th nipple set. Photographs were also taken at this point on subsequent
days of scanning on Day 7, 14, and 21.

Euthanization and Dissection. After photographs were taken and ultrasound imaging performed
on Day 21 under general anesthesia, rats were euthanized the same day in Western University
animal facilities in a carbon dioxide (CO2) chamber. A 15-blade used to make a longitudinal
midline incision from the xyphoid process down to pubis, and transversely to the mid-axillary line
at these landmarks. Dissection was carried along an alveolar plane, deep to the level of the
mammary fat pad and superficial to the parietal peritoneum. Dissection of the subcutaneous tissue
including the fat pads were carried down to the plane between dermis and subcutaneous fat.
Sections were subsequently weighed. An additional fat pad was taken as an intra-rat control in
each rat, of a single fat pad in the 5th nipple set. Two rats in each treatment group were planned
for immunohistochemistry, and these fat pads were placed in cassettes and 4% paraformaldehyde
at 4°in anticipation of fixing and sectioning. Three rats in each treatment group were planned for
qPCR experiments, and were thus placed in Eppendorf tubes, snap frozen, and kept at -80°C.

2.3 Immunohistochemistry. Fat pads were processed for paraffin histology slides. 4µm sections
were cut using a Microm HM 200 Ergostar Microtome (GMI; Ramsey, Minnesota, USA). Sections
were stained with hematoxylin and eosin (H&E) to confirm the presence of subcutaneous adipose
tissue. Adipocytes were identified as large vacuoles on imaging and visual inspection as paraffin
processing removed the lipid content. Sections were also stained with Masson’s Trichrome
(Sigma-Aldrich, St. Louis, Missouri). Antigen retrieval was performed using Antigen 2100
Retriever (Aptum Biologics Ltd, Southampton, UK). De-paraffinized tissue sections were
incubated with Anti-TGFb1 monoclonal antibody (1:50 dilution, Abcam ab92486) overnight at
4°C. The tissue sections were washed in PBS and then incubated with an anti-rabbit secondary
antibody conjugated to horseradish peroxidase (1:500 dilution, Abcam) for 1 hr at room
temperature. Colorimetric detection was then performed using nickel 3,3’-diaminobenzidine
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(DAB; 0.15 mg/ml in 0.03% H2O2; Sigma). Sections were counterstained with H&E. An
ascending ethanol series and xylene wash were performed before Cytoseal 60 (Thermoscientific)
was applied, followed by a glass cover slip application. In a similar fashion, the tissue sections
were incubated with anti-adiponectin monoclonal antibody (dilution 1:200, Abcam, ab22554) and
incubated with Goat anti-mouse secondary IgG (dilution 1:500, Dako, E3044) at 2 µg/ml for 2 hr
at room temperature. After washing, sections were incubated in streptavidin-horseradish
peroxidase (dilution 1:2000 Abcam, ab7403) for 30 min at room temperature. From each
experimental group, specimens were obtained from two rats. For each rat, both left and right
mammary fat pads were analyzed.
Immunohistochemistry Quantification. For TGFb1, using Aperio© ImageScope (Aperio
ePathology Solutions; http://www.aperio.com/), a total of five images per mammary fat pad, with
two slides per rat specimen were taken at 10x magnification. The images were transferred to
ImageJ 1.47 software. The ductal tissue was traced by hand via Wacom Intuos 4 (Portland, OR),
and the adipocytes were erased. Images were de-convoluted under the ‘H DAB’ setting to separate
the different colour channels to isolate the blue staining from hematoxylin and the positive brown
staining from TGFb1 antibody. A higher ratio of brown to blue staining would demonstrate greater
TGFb1 staining in those tissues. Quantification for adiponectin was done in a similar fashion, with
a total of five images per fat pad, and two slides per fat pad, were taken at 10.0X magnification,
one in each of four quadrants and one in the center region. Adipocytes were manually excluded,
leaving only the glands and surrounding stroma to be analyzed. The ratio of positively stained
brown cells to blue cells was used to determine the strength of adiponectin staining within each
image. This ratio was compared to the ratio from the image of the entire specimen, in order to
determine whether there was increased adiponectin staining near the glands.
Picrosirius Red Staining. Paraffin processed tissue sections of skin were stained for collagen using
Picrosirius Red staining Kit (Cat# 2490-250, Polysciences, Warrington, PA) by the Pickering Lab
at Robarts Research Institute. Again, two sections per rat (right and left fat pads) and two rats per
group were stained. Under polarized light, Picrosirius Red Staining is able to comment on collagen
deposition and bundling. Thus, expression of red, or denser bundling in the tissue is associated
with greater fibrosis. Conversely, blue reflects a lower density of collagen bundling.
Abrio 2.2 (Cri, Woburn, MA, USA) software was used for image acquisition. Slides were
examined under polarized light, and five randomized images at 40X magnification were taken of
each slide of areas that were composed primarily of adipocytes. Five additional images at 40X
magnification were taken in a randomized fashion of areas that were composed primarily of ductal
tissue. Image acquisition and analysis was performed by a blinded assessor. Analysis was carried
out in Photoshop CC (Adobe, Mountain View, California, USA). Ducts were isolated by manually
cropping out adipocyte tissue that surrounded the ductal tissue. The total pixel count of this area
was then recorded. Expression was red and blue was then isolated. Expression of extent of collagen
deposition was thus examined by observing the amount of red expression, with respect to area and
corresponding blue expression. The total number of red pixels multiplied by mean value (in other
words, intensity), was used to provide a measure of absolute red expression.
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2.4 qPCR analysis. Mammary gland RNA was isolated using Trizol (Thermo-Fisher, Waltham,
MA) following manufacturer’s instructions and homogenized on ice. RNA was quantitated by
spectroscopy (NanoDrop, Thermo-Fisher). Reverse transcription was performed with SuperScript
VILO cDNA Master Mix (Thermo-Fisher). Reactions consisting of 1000ng RNA, 4µL Master
Mix, and sufficient nuclease-free water to make the reaction up to 20µL were prepared and
incubated according to the kit manual. The resulting cDNA was diluted 1:10 in nuclease-free
water. Quantitative PCR (qPCR) was performed with SsoAdvanced SYBR Green Supermix (BioRad, Hercules, CA) using 10µL master mix with 1µL of forward and 1µL reverse primer, each at
10 ng/µL, and 8µL of diluted cDNA per reaction. qPCR was run on a Mx3000P system (Agilent
Technologies, Santa Clara, CA) with 40 cycles at an annealing temperature of 60°C. Specificity
of amplification was confirmed with melting curve analysis. Expression was calculated using the
2−∆∆Ct method relative to Gapdh expression and normalized to expression in the non-irradiated,
untreated samples. Primer sequence: Gapdh forward: CTCATGACCACAGTCCATGC, Gapdh
reverse: TTCAGCTCTGGGATGACCTT, TGFb1 forward: ATGACATGAACCGACCCTTC,
TGFb1
reverse:
ACTTCCAACCCAGGTCCTTC,
Collagen-1
forward:
GAGCGGAGAGTACTGGATCG, Collagen-1 reverse: TACTCGAACGGGAATCCATC,
Collagen-3
forward:
TGATGGGATCCAATGAGGGAGA,
Collagen-3
reverse:
GAGTCTCATGGCCTTGCGTGTTT, Adiponectin forward: TAAGGGTGACCCAGGAGATG,
Adiponectin
reverse:
GGAACATTGGGGACAGTGAC,
Perilipin
forward:
TGCAAFCATTCTGACAAGG, Perilipin reverse: GGAGCCTTCTGCATCTTTTG, PPARg
forward AGAGCTGACCCAATGGTTGC, PPARg reverse: AAGGCTCTTCATGTGGCCTG.
2.5 Skin Assessments. Photographs of the rats were taken at Day 0, 7, 14, and 21 after ultrasound
gel was wiped off as described above. Images of all the rats in different groups over the time points
were then uploaded onto Qualtrics, an online survey software tool (Provos, Utah, USA) and
randomized. The survey was then sent to a staff physician with expertise on skin changes
associated with radiation damage, as well as two resident physicians in plastic surgery. The
reviewers were blinded to the treatment groups and day of treatment.
2.6 Volume assessment. Weights of the rats were recorded at Day 0, 7, 14, and 21. The 4th set of
mammary fat pads and additional single fat pad from 5th set of mammary fat pads were dissected
from rats and weighed. High frequency ultrasound images were analyzed using Vevo2100
ultrasound Imaging System. Each rat underwent ultrasound at Days 0, 14, and 21. As mentioned,
only two of five rats in each group were analyzed on Day 7. For each fat pad, the midline was
marked as the center of the nipple. Measurements of the fat pad, as well as the fat pad with the
skin were taken at 2mm proximal and 2mm distal to the marked midline in Vevo2100 software.
2mm was chosen because it was the closest measurement that was consistently possible to the
nipple yet avoid the mammary fat pad distortion associated at the level of midline due to the ducts
feeding the nipple. 3D reconstruction. The same midline measurement was used as that used for
thickness measurements in Vevo2100 software. The fat pad was contoured using the lasso tool at
midline, at 5mm proximal and at 5mm distal to the mammary fat pad. These measurements were
taken as the fat pads were consistently captured within these parameters – often further than that,
the fat pad would “drop off” if the rat was smaller in size. The software was programmed to fill in
the rest of the fat pad between these contour levels. The contours were checked by scrolling
through the images (step size of each images 0.083mm) and adjusted as needed to reflect the
mammary fat pads as accurate as possible.
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2.7 Statistical analysis. Statistical signifance between groups were assessed using 1-tailed
indepedent sampled “t-test”. Values were considered to be significant if p < .05.

3. Results
The irradiated rats exhibited significantly higher scores on the Kumar Scale, a skin assessment
scale previously used measure of cutaneous radiation injury for animals (Supp. Figure 1)37,
amongst all days when compared to non-irradiated rats when evaluated by a clinical expert in
radiation-skin changes in a blinded fashion (***p=.005; Figure 1). When specific days were
analyzed, the radiation oncologist expert observed differences in the two groups at Day 7 and 21
(equal variances not assumed; *p=.0125 and **p=.0045 respectively). The clinical expert also
found a difference (*p=.022) between the two groups at Day 7 using the Radiation Therapy
Oncology Group (RTOG) toxicity scoring system, a commonly used scoring system for radiation
skin reaction changes12. These results show that the applied dose of radiation resulted in acute and
clinically visible changes in the exposed skin. To determine if this dose also resulted in chronic
skin fibrosis typical of radiofibrosis observed in human skin, pro-fibrotic markers were measured.
An increased density of collagen fibrils is typical of radiofibrosis. This property was measured by
Picrosirius red staining of histology sections that were imaged with polarized microscopy. As
shown in Figure 2, radiation induced a strong increase in collagen fibril density. (*p =.025). A
similar result was observed when collagen was detected using Masson’s trichrome staining as well.
There was a trend (p=.07) towards increased expression of active TGFb1 in immunohistochemical
studies of mammary fat pad sections. TGFb1 is typically expressed within the first week of
damage, and so it is not un-expected that a significant change was not observed in this series of
experiments (Figure 2).
To further probe pro-fibrotic changes in the radiated rodent skin, qPCR analyses of TGFb1 and
Collagen 1 and collagen 3 mRNA were next evaluated. An increase in the Collagen-1 to Collagen3 ratio is typical of scarred fibrotic tissue. Adipogenic markers were also evaluated since radiation
has been observed to inhibit adipogenesis. Markers included the “master” adipogenic transcription
factor, PPARg and one of its targets the adipokine adiponectin, However, significant changes in
mRNA expression was not observed in the control vs. radiated groups (Figure 3).
Since a goal of this study was to reduce tissue fibrosis in order to create a more favorable
microenvironment to support autologous fat grafts, the effect of RHAMM function blocking
peptides, which have previously been shown to inhibit fibrosis and promote adipogenesis55,63,78, on
radiofibrosis in this rat model was next assessed. Visible Skin changes were not appreciably
different between the radiated and peptide treated groups when the cumulative score was assessed
using the Kumar and RTOG scales (representative images Supp. Figure 3, 4).
However, peptide treated radiated skin strongly reduced collagen fibril formation as detected by
picrosirius red staining (*p=.003). Masson’s trichrome staining qualitatively showed a similar
effect. Active TGFb1 trended to a lower level in the peptide group (p=.08). These results show
that the RHAMM function blocking peptide strongly reduces radiofibrosis as detected by collagen
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fibril formation (Figure 4).
In order to assess if these changes in tissue fibrosis are accompanied by altered adipogenesis,
adipokine expression was analysed by QPCR. These included ADIPOQ, and PPARg55. We also
analyzed the mammary fat pad for volume changes using high frequency ultrasound but these were
not significant (data not shown).
QPCR analyses showed a significant increase in the adipokine adiponectin (Figure 5) (*p=.015).
There was a trend towards increased expression of PPARg in the peptide treated group (p=.06) and
a trend in an increase of PPARg expression (Figure 5). These results suggest that the RHAMM
function blocking peptide promotes a pro-adipogenic microenvironment.
4. Discussion
We describe in this study radiation induced inflammatory (dermatitis) and fibrotic changes in
mammary fat pads. Other studies that have also observed radiodermatitis, radiation-induced
lesions, and radiofibrosis in different animal models, using different radiation dosages. De
Andrade et al. used 10 Gy, 40 Gy, and 60 Gy on dorsal excisional wounds in rats that resulted in
macroscopic and microscopic injuries to rat skin with increasing doses of radiation. In wounds,
visible skin changes, increased collagen fibril formation, and increased TGFβ1 expression
observed as early as day 5 even at lower doses104. Chronic changes in response to ionizing radiation
have also in other animal models. For example, in leg contracture models, mice exhibit progressive
leg contracture and fibrosis when administered single doses of radiation between 20-80 Gy105.
However, to our knowledge, our study is the first report of radiation induced mammary fat pad
fibrosis.
Contrary to previous belief, radiation fibrosis is currently thought to be a dynamic process,
characterized by constant remodeling and long-term fibroblast activation. In normal repair,
fibroblasts are transiently activated into myofibroblasts to facilitate wound remodeling.
Terminally differentiated myofibroblasts undergo apoptosis and normal tissue architecture is
mostly restored. However, in fibrotic tissue, chronic myofibroblast activation is observed, which
is thought to result from elevated levels of growth factors including TGFβ1, PDGF, TNFa,
bFGF’s, GM-CSF, IL-1, IL-4, and CTGF106,107. In animal models of lipodystrophy and
scleroderma, these pro-fibrotic cytokines reduce the survival of adipocyte progenitor cells.
Adipogenesis is also restrained by the rigid microenvironment produced by myofibroblasts ability
to promote collagen fibrillogenesis. Loss of adipocytes also contributes to progressive tissue
fibrosis since many adipokines are anti-fibrotic. This is particularly true of adiponectin. Our results
support this connection between adipocytes and fibrosis since the RHAMM function blocking
peptide reduced fibrosis concomitantly with an increase in adiponectin expression.
To date, there is no approved clinical treatment for radiofibrosis and few current options are
available for restricting or reversing tissue fibrosis resulting from other forms of tissue injury.
Although TGFβ1 is considered a master switch for promoting myofibroblast differentiation and
survival and for reducing anti-fibrotic adipokine production, this cytokine has not been useful for
clinical control of fibrosis likely because of its ubiquitous expression and multifunctional nature.
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Another potential target that has emerged is PPARg, which regulates both inflammatory and
fibrosis processes. In particular, the PPARg agonist rosiglitazone has been reported to protect mice
against radiation induced inflammation and reduced expression of both TGFβ-1 and Collagen-1116.
However, the use of rosiglitazone is currently restricted in humans due to trials showing increased
drug related cardiovascular toxicity. One of the PPARg target genes, adiponectin, may be a more
promising approach for reducing some forms of tissue fibrosis and clinical trials are currently
ongoing for liver disease 117. However, in animal models, adiponectin did not appear to play a role
in radiation induced intestinal damage in mice118 and its anti-fibrotic effects may be more specific
to injury stimulus. We propose that blocking RHAMM function using mimetic peptides is an
efficacious alternative approach to controlling tissue fibrosis resulting from radiation and also from
other forms of tissue damage. RHAMM function blocking peptides are predicted to be particularly
useful for reducing radiofibrosis in breast tissue since they create a microenvironment that supports
adipogenesis. This is predicted to both contribute to a reduction in fibrosis (e.g. through elevated
production of adiponectin) and to provide a method for supporting the survival and differentiation
of adipocytes in autologous fat grafts. To date, RHAMM function blocking peptides have a good
safety profile in animal models likely due to the restricted expression of this protein in homeostatic
tissues. RHAMM expression is an integral part of the response of tissues to stress and to disease.
Its primary functions appear to be control cellular migration and mesenchymal differentiation
during repair processes. Future work with these mimetic peptides will be directed towards
assessing their ability to promote pre-adipocyte survival and differentiation in fibrotic
microenvironments.
We did not observe an increase in either the expression or activation of TGFβ1 or an altered
Collagen-1:Collagen-3 ratio that has been reported for other animal models of radiation. TGFβ1
has been detected in skin as early as 6 hours after g-radiation111. Increased levels of TGFβ1 were
also found at 6 hours post-irradiation in other studies, which returned to basal level within 48 hours
and increased after 14 days. In mouse mammary glands, one team has found that whole body
irradiation induced immunoreactivity at 1 hour, and persisted for 7 days. In addition, they found
that irradiation specifically generates the active (versus latent) TGFβ1, suggesting that low and
moderate doses of radiation induced the activation of latent TGFβ1 in the mouse mammary
gland112,113. Martin et al. describes two types of fibrosis: an immature, active, and inflammatory
fibrotic tissue examined in most studies, versus a non-inflammatory and poorly cellularized
fibrotic tissue that correspond to studies of samples 10-20 years after irradiation33. Of note, the
young fibrosis samples contained a high proliferation rate of myofibroblasts, and a high secretion
of TGFβ1, whereas the older type of fibroblasts exhibited reduced proliferation and low secretion
of TGFβ1114,115. Future studies would look at sacrificing animals within the one-week mark as
TGFβ1 is an early inflammatory marker, and after 6 months as perhaps a more accurate
representation of chronic radiation fibrosis. The studies above support using TGFβ1, Collagen-1
and 3 as markers of fibrosis.
Previous studies showed that the injection of RHAMM function blocking peptides result in a
detectable increase in mammary fat pad size as measured by micro computer tomography
(MicroCT)55. High frequency ultrasound is a more common imaging modality that has recently
evolve as a result of more sophisticated technology and computer programs123,124. High frequency
transducers (>15 MHz) have been used to successfully study the vascularization of expansion of
lesions in the skin lesions, skin diseases such as psoriasis, scleroderma, erythema nodosum, among
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others123. More recently, Santolo et al. has evaluated the use of Doppler ultrasound examination
(ECD) in autologous adipose tissue filling by a plastic surgeon in the setting of post-surgical, posttraumatic, and post-burn scars in patients124. They found that they were able to have quantitative
data with ultrasound examination representing various skin and subcutaneous layers in serial
evaluations after lipofilling procedure, and thus subsequent average percentage of one-year
survival of autologous implanted fat was possible. Other authors have used ultrasound as a noninvasive, quick, and low-cost technique to study fat necrosis, and subcutaneous tissue for preoperative planning and document post-operative results in the context of lipofilling125–127.
However, although ultrasound has been used to study lipofilling and adipose tissue in the previous
studies, to our knowledge, our study was the first attempt to use high frequency ultrasound to
quantify the volume of a rodent mammary fat pad. Attempts were made to set up rats in the same
position for every measurement, but even so, slight movement of the rat or centering on nipple
may not be exact each time and could affect the measurement. Slight angulation and rotation may
have affected the field of capture as well. Efforts to bypass this were made by measuring thickness
of mammary fat pad in addition to contouring the volume, whereby the irregularities around the
nipple wouldn’t confound the accuracy of measurement. Other potential confounders include
variation in ultrasound gel and pressure of the, potentially affecting the consistency in
measurement of the fat pad secondary to differences in compression. Lastly, as with human breast
volume, there exist natural variations in rat volume, and so perhaps we were unable to detect
significant differences due to this with our sample size. Percentage change within rat weights,
volume, and thicknesses were used to control for this, but again we saw no differences between
the studied groups. We would recommend future studies repeat with a greater sample size, and
have it compared to other methods of volume assessment.
From an oncological perspective, there has traditionally been concern with the safety of fat grafting
at the breast level. Most of this concerned the potential for necrosis and micro-calcification of
breast tissue that would be misleading on radiographic mammography11. In addition, the
interaction of grafted adipose tissue with host cancer cells, as well as the long-term effects of fat
and cell transplantation in a microenvironment of highly reproductive tissue or residual tumour
cells are unknown11,141–143. Recommendations thus exist for patient selection for autologous fat
grafting to the breast: risk factors such as BRCA-1, BRCA-2, positive personal or family history
of breast cancer would warrant mammography prior to surgery11,144. Fat grafts enriched with
processed adipose derived stem cells have been used in breast reconstruction following
mastectomy and in non-oncologic breast augmentation without adverse outcome, however no long
term data is present145,146. More research in long-term clinical studies in this area is needed, and it
is suggested that until then, conventional fat grafting is safe in certain subgroups of patients,
whereas an increase in stem cell fraction through various means cannot be recommended at
present11.

5. Conclusions
Radiation damaged skin as a result of radiotherapy is characterized by both acute and chronic
changes, and can be replicated in an animal model. Here, a model for radiation-induced mammary
fat pad has been developed, with an increase in observational skin changes, and increased collagen
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bundling and expression of fibrotic marker TGFβ. RHAMM blocking peptides (NPI-110) have
been shown to promote adipogenesis and decrease fibrosis in previous animal models. Here, we
show that RHAMM blocking peptide NPI-110 increase expression of adipogenetic markers and
decrease fibrotic markers in such a rat model of radiation-induced mammary fat pad fibrosis. These
results support the further investigation of this approach to ultimately reduce radiofibrosis and
improve breast reconstruction in breast cancer patients.
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Figure 1. Radiation group had significantly greater clinically detectable skin changes than
non-irradiated control group with the Kumar scale and RTOG skin scoring systems. Skin
assessments were performed by a radiation oncologist on control and irradiated rats in all days,
using the Kumar and RTOG scoring systems A. Clinical Expert Evaluation mean score across all
days with Kumar scale (***p=.0005) B. Clinical Expert Evaluation with Kumar Scale, days
separated (**p=.0045; *p=.0125) C. Clinical Expert Evaluation mean score across all days with
RTOG scale (**p=.0015) D. Clinical Expert Evaluation with RTOG scale, days separated
(*p=.022) Values are the Mean, analysis with 1-tailed t-tests. n = 5 rats.
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Figure 5. Markers of fibrosis are increased in irradiated groups compared to non-irradiated
control in immunohistochemical studies. Paraffinized sections in control and irradiated rats
euthanized at Day 21 were stained for markers of fibrosis A. Representative images stained with
H&E B. Representative images stained with Picrosirius Red, red indicating denser collagen
bundling and networks, at 40x C. Representative images stained with Masson’s Trichrome D.
Representative images stained with TGFβ1, brown is positive staining for TGFβ1, at 5x E. The
percentage staining per an area that expressed red when stained for Picrosirius Red (*p=.025) F.
The percentage staining per an area of fat pad at day 21 for TGFβ1 (p=.07). Values are the Mean,
analysis with 1-tailed t-tests. n = 5 rats, 5 images/fat pad, two fat pads/rat.

106

Figure 6. No difference in fibrotic markers were found in qPCR studies. Real time PCR was
performed for markers of fibrosis in non-irradiated (control group) and irradiated rat whole
mammary fat pads A. TGFβ1 (*p=.045) B. Collagen-1:Collagen-3 (p=.118) C. PPARg (p=.085)
D. Adiponectin (p=.063). Values are the Mean, analysis with 1-tailed t-tests. n = 3 rats, 3 technical
replicates/fat pad, two fat pads/rat.
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Figure 7. Markers of fibrosis are decreased in peptide-treated groups compared to nonpeptide treated groups amongst irradiated rats in immunohistochemical studies. Paraffinized
sections in peptide and non-peptide treated groups euthanized at Day 21 were stained for markers
of fibrosis A. Representative samples stained with H&E B. Representative samples stained with
Picrosirius Red, red indicating denser collagen bundling and networks, at 40x C. Representative
samples stained with Masson’s Trichrome D. Representative samples stained with TGFβ1, brown
is positive staining for TGFβ1, at 5x E. The percentage staining per an area that expressed red
when stained for Picrosirius Red (*p=.003) F. The percentage staining per an area of fat pad at day
21 for TGFβ1 (p=.078). Values are the Mean, analysis with 1-tailed t-test. n = 5 rats, 5 images/fat
pad, two fat pads/rat.
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Figure 5. Peptide NPI-110 increased markers of adipogenesis amongst irradiated groups in
qPCR studies. Real time PCR was performed for markers of adipogenesis in peptide and nonpeptide treated groups in irradiated rats A. Adiponectin (*p=.015) B. PPARg (p=.055). Values are
the mean, analysis with 1-tailed t-test. n = 3 rats, 3 technical replicates/fat pad, two fat pads/rat.
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Appendix (Supplemental Figures)
Day 0

Day 7

Day 14

Day 21

Control

Radiation

Supplemental Figure 1. Representative Images of right 4th mammary fat pad rats in control
and radiation group at Days 0, 7, 14, and 21.
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Supplemental Figure 2. A. Kumar scale B. RTOG scale
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Day 0

Day 7

Day 14

Day 21

Radiation

Radiation
+ Peptide

Supplemental Figure 3. Images of right 4th mammary fat pad rats in radiation and
radiation + peptide group at Day 0, 7, 14, 21 (Rat 4 and 5 of each group respectively).
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Supp Figure 4: Peptide (NPI-110) did not reduce severity of clinically appreciable skin
changes in irradiated rats. Skin assessments were performed by an expert clinician treated and
non-peptide treated groups amongst irradiated rats using the Kumar Scale and RTOG scale A.
Clinical Expert Evaluation mean score across all days using Kumar scale (p=.593) B. Clinical
Expert Evaluation mean score across all days using RTOG scale (p=.231) C. Clinical Expert
Evaluation using Kumar Score, days separated D. Clinical Expert Evaluation using RTOG score,
days separated. Values are the Mean, analysis with 2-tailed t-tests. n = 5 rats.
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